

vinyl acetate and/or a polyester. The composition also comprises a coating on the fibres. The coating is a **basement membrane** component, agar, agarose, gelatin, a glycosaminoglycan a collagen, gum arabic, fibronectin, laminin, hyaluronic acid and/or an attachment peptide. The cells are chondrocyte cells, fibroblast cells capable of differentiation into chondrocytes, or bone precursor cells capable of differentiation into chondrocytes.

USE - The cell scaffold compositions may be used for production of joint relinings, growth of elastic cartilage for plastic or reconstructive replacement of cartilage structures (e.g. the **ear** or the **nose** ), or for repair of large bone defects.

ADVANTAGE - The compositions can be cast or molded into desired shapes, or can be manipulated at the time of **implantation**. The cells can retain their normal morphology and cell function.

Dwg. 0/10

Derwent Class: A96; B04; D16; D22; P32  
International Patent Class (Main): C12N-011/08  
International Patent Class (Additional): A61F-  
C12N-005/00

17/34/4 (Item 4 from file: 350)

DIALOG(R)File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.  
008461275

WPI Acc No: 1990-348275/199046

Formation of cartilage structures - by attaching chondrocyte cells to biocompatible matrix in nutrient environment

Patent Assignee: LANGER R S (LANG-I); VACANTI C A (VACA-I); VACANTI J P (VACA-I); CHILDRENS MEDICAL CENT (CHIL-N); MASSACHUSETTS INST TECHNOLOGY (MASI ); CHILDRENS HOSP BOSTON (CHIL-N); CHILDRENS MEDICAL CENTER CORP (CHIL-N); CHILDRENS HOSP ROSTON (CHIL-N)

Inventor: LANGER R S; VACANTI C A; VACANTI J P

Number of Countries: 020 Number of Patents: 011

Patent Family:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
WO 9012603	A		45		
Designated States (National): AU CA FI JP KR NO					
Designated States (Regional): AT BE CH DE DK ES FR GB IT LU NL SE					
EP 469070	A				
Designated States (Regional): AT BE CH DE ES FR GB IT LI LU NL SE					
JP 4505717	W	45	A61L-027/00		Based on patent WO 9012603
AU 635025	B		A61L-027/00		Previous Publ. patent AU 9055568
					Based on patent WO 9012603
JP 94006155	B2		A61L-027/00		Based on patent JP 4505717
					Based on patent WO 9012603
EP 469070	B1	E	22	A61L-027/00	Based on patent WO 9012603
Designated States (Regional): AT BE CH DE DK ES FR GB IT LI LU NL SE					
CA 2051663	C		C12N-011/00		
DE 69028524	E		A61L-027/00		Based on patent EP 469070
					Based on patent WO 9012603
ES 2095252	T3		A61L-027/00		Based on patent EP 469070

Abstract (Basic): WO 9012603 A

A system for growing a cartilaginous structure is claimed comprising a biocompatible matrix in a nutrient environment and chondrocyte cells attached to the matrix, where the matrix is structured to provide free exchange of nutrients and waste to the attached cells in the absence of vascularisation. The matrix may be formed from eg. polyanhydrides, polyorthoesters, polyglycolic acids, polylactic acids, collagen, teflon, nylon, ethylene vinyl acetate or polyesters. The matrix may be coated with eg. basement membrane components, agar, agarose, gelatin, gum arabic, collagens, fibronectin, laminin, hyaluronic acid, glycosaminoglycans or attachment peptides.

Also claimed is a method for making a cartilaginous structure by providing a biocompatible matrix in a nutrient environment and attaching cartilage cells to the matrix.

USE/ADVANTAGE - The matrices can be formed of the required shape and flexibility for reconstructive and plastic surgery and are able to produce high cell densities. They can be used in vivo for eg. the growth of hyaline cartilage for joint relinings, the growth of elastic cartilage for plastics or reconstructive replacement of cartilage structures or repair of large bone defects. They can also be used for the prodn. of bioactive molecules in vitro, eg. proteinase inhibitors and collagenase inhibitors.

(Dwg. 0/10

Abstract (Equivalent): EP 469070 B

Use of a biocompatible synthetic polymeric matrix, the matrix being formed of fibres or a fibrous mesh and made from either a non-degradable material or a biodegradable material which degrades by hydrolysis or a combination thereof and chondrocytes, fibroblasts or bone-precursor cells attached to the matrix, wherein the matrix is structured to provide free exchange of nutrients and waste to the attached said cells in the absence of vascularisation in the manufacture of a cartilaginous structure or surface, or a bone structure, for implantation in, or addition to, a patient, wherein the said matrix is formed into a desired shape of a cartilaginous structure or surface or for repair of a bone defect in the said patient.

(Dwg. 0/10

Abstract (Equivalent): US 5041138 A

Process for replacing or repairing cartilage structures comprises immobilising living cells on a rigid or flexible biocompatible, biodegradable synthetic polymer matrix, pref. coated with membrane components; proliferation of the cells in vitro; and implantation. Cells which propagate under these

conditions are cartilage, bone, skin and nerve cells. USE - The process is applicable to the repair or replacement of cartilage damaged by inflammation, trauma, ageing or congenital defect, or replacement of bone, **nose** and **ear** tissues, etc. (8pp)

Derwent Class: B04; D16; D22; P32; P34

International Patent Class (Main): A61L-027/00; C12N-011/00

International Patent Class (Additional): A61F-002/30; A61K-037/00;  
C07C-245/00; C12N-005/00

File 350:Derwent WPIX 1963-2003/UD,UM &amp;UP=200351

File 347:JAPIO Oct 1976-2003/Apr(Updated 030804)

File 371:French Patents 1961-2002/BOPI 200209

Set Items Description

S1	28	AU='BADYLAK S' OR AU='BADYLAK S F'
S2	10	AU='SPIEVACK A R'
<b>S3</b>	<b>1</b>	<b>S1 AND S2</b>
S4	251	VOCAL()CORD? ?
S5	109	SUBMUCOSA
S6	378	(BASEMENT OR HYALINE) ()MEMBRANE? ? OR (BASAL OR BASEMENT) (-) LAMINA
S7	36	S1:S2 NOT S3
S8	0	S7 AND S4
S9	18	S7 AND S5:S6
S10	772857	HEAD OR NECK
<b>S11</b>	<b>1</b>	<b>S9 AND S10</b>
<b>S12</b>	<b>17</b>	<b>S9 NOT S11</b>

3/34/1 (Item 1 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

013270038

WPI Acc No: 2000-441944/200038

Repair or replacement of head and neck tissues involves removing the damaged or diseased portion of the tissue, and replacing it with a graft construct of vertebrate submucosa or basement membrane

Patent Assignee: PURDUE RES FOUND (PURD )

Inventor: **BADYLAK S F** ; **SPIEVACK A R**

Number of Countries: 090 Number of Patents: 004

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200032254	A1	20000608	WO 99US28300	A	19991201	200038 B
AU 200027068	A	20000619	AU 200027068	A	19991201	200044
GB 2360948	A	20011010	WO 99US28300	A	19991201	200167
			GB 200114322	A	20010612	
AU 761153	B	20030529	AU 200027068	A	19991201	200346

Priority Applications (No Type Date): US 98110465 P 19981201; US 98110401 P 19981201

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

WO 200032254 A1 E 26 A61L-027/38

Designated States (National): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SL SZ TZ UG ZW

AU 200027068 A Based on patent WO 200032254

GB 2360948 A A61L-027/60 Based on patent WO 200032254

AU 761153 B A61L-027/38 Previous Publ. patent AU 200027068

Based on patent WO 200032254

Abstract (Basic): WO 200032254 A1

NOVELTY - Repair or replacement of head and neck tissues involves removing the damaged or diseased portion of the tissue, and replacing the removed portion with a graft construct containing vertebrate submucosa or basement membrane.

DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for the use of submucosa or vertebrate basement to manufacture a non-immunogenic tissue graft composition for repairing vocal cords and other soft tissues of the head and neck.

USE - For repairing or replacing head and neck tissues.

ADVANTAGE - The graft constructs induce proliferation or growth of endogenous cells to form native tissues to invade structure, including an epithelial cell layer, connective tissue, and functional muscle.

pp; 26 DwgNo 0/0

Technology Focus:

TECHNOLOGY FOCUS - INSTRUMENTATION AND TESTING - Preferred Components: The graft construct formed as a multilayered homolaminate comprises a single thickness sheet of submucosa or a vertebrate basement membrane. The submucosa is 2-12 (preferably 4-6) layers of urinary bladder, stomach, or preferably intestinal. The intestinal submucosa comprises the tunica submucosa delaminated from the tunica muscularis and the luminal portion of the tunica mucosa. Preferred Tissues: The head and neck tissues are vocal cord, larynx, palette, attached gingiva, nasal, or auricular tissues.

Derwent Class: D22; P32; P34

International Patent Class (Main): A61L-027/38; A61L-027/60

International Patent Class (Additional): A61F-002/10; A61F-002/20

11/34/1 (Item 1 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.  
013980873

WPI Acc No: 2001-465087/200150

Devitalized matrix for inducing repair of tissue defects in mammal, comprises isolated devitalized mammalian epithelial basement membrane and tunica propria immediately adjacent to basement membrane

Patent Assignee: ACELL INC (ACEL-N)

Inventor: SPIEVACK A R

Number of Countries: 095 Number of Patents: 017

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
WO 200145765	A1	20010628	WO 2000US34938	A	20001220	200150	B
AU 200125906	A	20010703	AU 200125906	A	20001220	200164	
EP 1239897	A1	20020918	EP 2000989397	A	20001220	200269	
			WO 2000US34938	A	20001220		
US 20030054022	A1	20030320	US 99171733	P	19991222	200323	
			US 2000691345	A	20001018		
			US 2002280158	A	20021025		
US 20030059404	A1	20030327	US 99171733	P	19991222	200325	
			US 2000691345	A	20001018		
			US 2002280430	A	20021025		
US 20030059405	A1	20030327	US 99171733	P	19991222	200325	
			US 2000691345	A	20001018		
			US 2002280552	A	20021025		
US 20030059406	A1	20030327	US 99171733	P	19991222	200325	
			US 2000691345	A	20001018		
			US 2002280582	A	20021025		
US 20030059407	A1	20030327	US 99171733	P	19991222	200325	
			US 2000691345	A	20001018		
			US 2002280678	A	20021025		
US 20030059409	A1	20030327	US 2000691345	A	20001018	200325	

US 20030059410	A1	20030327	US 2002280802	A	20021025	
			US 99171733	P	19991222	200325
			US 2000691345	A	20001018	
			US 2002280818	A	20021025	
US 20030059411	A1	20030327	US 99171733	P	19991222	200325
			US 2000691345	A	20001018	
			US 2002281035	A	20021025	
US 20030064111	A1	20030403	US 2000691345	A	20001018	200325
			US 2002280935	A	20021025	
US 20030064112	A1	20030403	US 99171733	P	19991222	200325
			US 2000691345	A	20001018	
			US 2002281372	A	20021025	
US 6576265	B1	20030610	US 99171733	P	19991222	200340
			US 2000691345	A	20001018	
US 6579538	B1	20030617	US 99171733	P	19991222	200341
			US 2000691590	A	20001018	
JP 2003518078	W	20030603	WO 2000US34938	A	20001220	200346
			JP 2001546704	A	20001220	
US 20030133916	A1	20030717	US 99171733	P	19991222	200348
			US 2000691345	A	20001018	
			US 2003337152	A	20030107	

Priority Applications (No Type Date): US 2000691590 A 20001018; US 99171733 P 19991222; US 2000691345 A 20001018; US 2002280158 A 20021025; US 2002280430 A 20021025; US 2002280552 A 20021025; US 2002280582 A 20021025; US 2002280678 A 20021025; US 2002280802 A 20021025; US 2002280818 A 20021025; US 2002281035 A 20021025; US 2002280935 A 20021025; US 2002281372 A 20021025; US 2003337152 A 20030107

#### Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
WO 200145765	A1	E	23	A61L-027/36	

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW

AU 200125906 A A61L-027/36 Based on patent WO 200145765

EP 1239897 A1 E A61L-027/36 Based on patent WO 200145765

Designated States (Regional): AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR

US 20030054022 A1 A61F-002/00 Provisional application US 99171733  
Cont of application US 2000691345

US 20030059404 A1 A61K-035/37 Provisional application US 99171733  
Cont of application US 2000691345

US 20030059405 A1 A61K-035/37 Provisional application US 99171733  
Cont of application US 2000691345

US 20030059406 A1 A61K-035/37 Provisional application US 99171733  
Cont of application US 2000691345

US 20030059407 A1 A61K-035/37 Provisional application US 99171733  
Cont of application US 2000691345

US 20030059409 A1 A61K-035/37 Cont of application US 2000691345

US 20030059410 A1 A61K-035/37 Provisional application US 99171733  
Cont of application US 2000691345

US 20030059411 A1 A61K-035/37 Provisional application US 99171733  
Cont of application US 2000691345

US 20030064111 A1 A61K-035/37 Cont of application US 2000691345

US 20030064112 A1	A61K-035/37	Provisional application US 99171733 Cont of application US 2000691345
US 6576265 B1	A61K-035/38	Provisional application US 99171733
US 6579538 B1	A61K-035/22	Provisional application US 99171733
JP 2003518078 W	26 A61K-035/12	Based on patent WO 200145765
US 20030133916 A1	A61K-045/00	Provisional application US 99171733 Cont of application US 2000691345

Abstract (Basic): WO 200145765 A1

NOVELTY - A devitalized matrix for inducing repair of tissue defects in an mammal, comprises an isolated devitalized mammalian epithelial **basement membrane** and tunica propria immediately adjacent to **basement membrane**.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(i) Method for inducing repair of tissue defect in mammal which involves providing a devitalized matrix to defect site;

(ii) A devitalized composition which comprises a mammalian epithelial **basement membrane** and tunica propria. The membrane and tunica propria are delaminated from cells of epithelium and abluminal portions of tunica propria; and

(iii) Manufacture of devitalized tissue graft composition which involves soaking epithelial tissue in a de-epithelializing solution to form a de-epithelialized tissue having **basement membrane** and abrading the tissue on an abluminal surface of tissue to form delaminated tissue. The delaminated tissue comprises a portion of epithelial **basement membrane** which induces endogeneous tissue restoration.

USE - For inducing restoration of diseased or defective cardiac tissue such as a portion of interventricular septum or cardiac valve such as pulmonic valve, aortic valve, right atrioventricular valve or left atrioventricular valve and myocardium (all claimed), epicardium, endocardium, pericardium and superior and inferior vena cava, and for inducing repair or replacement of tissue like connective tissues such as ligaments, tendons, cartilage, bone, joints, and muscle, epithelial tissues such as urinary bladder, and other tissues of urogenital tract, stomach, esophagus, and other tissues of gastrointestinal tract, liver, nervous tissue, tissues of **head** and **neck**, skin, and other tissues.

ADVANTAGE - The inclusion of epithelial **basement membrane** in devitalized mammalian tissue regenerative composition provides improved in vivo endogeneous cell propagation and tissue restoration. The induction method prevent complete loss of epithelial **basement membrane**. The tissue regenerative composition is applied as sheet or multilayer sheet of material, as extract in gel form, powder, tube, strips, cords or struts.

pp; 23 DwgNo 0/1

Technology Focus:

TECHNOLOGY FOCUS - BIOLOGY - Preferred Membrane: The **basement membrane** is derived from urinary bladder and small intestine.

Preferred Matrix: The matrix is sutured at tissue defect, injected into tissue defect, applied to the tissue defect fixation device or mixed with a pharmaceutical agent. The matrix is shaped to conform to diseased or defective cardiac tissue. The matrix comprises an injectable form of matrix, and a pharmaceutical agent. The matrix restores or replaces a portion of interatrial septum.

Preferred Method: The de-epithelializing solution comprises 1.0 N saline. The abluminal surface comprises a tissue surface deeper than

epithelial basement membrane. The restoration of diseased or defective cardiac tissue further comprises induction of endogenous epithelial repair.

Derwent Class: B04; B07; C06; D16; D22; P32; P34  
International Patent Class (Main): A61F-002/00; A61K-035/12; A61K-035/22; A61K-035/37; A61K-035/38; A61K-045/00; A61L-027/36  
International Patent Class (Additional): A61K-035/34; A61K-035/36; A61L-027/00; A61P-043/00

**12/26, TI/1 (Item 1 from file: 350)**

DIALOG(R)File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.  
013240272

WPI Acc No: 2000-412146/200035

**Suppressing cell mediated immune response and protecting immunogenic biomaterials from the host immune system using vertebrate submucosa**

**12/26, TI/2 (Item 2 from file: 350)**

DIALOG(R)File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.  
013099536

WPI Acc No: 2000-271408/200023

**Improved tissue construct comprising submucoas of warm-blooded vertebrate and pre-selected eukaryotic cells, useful for enhancing repair of damaged or diseased tissue in vivo**

**12/26, TI/3 (Item 3 from file: 350)**

DIALOG(R)File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.  
012531265

WPI Acc No: 1999-337371/199928

**New composition comprising vertebrate submucosal tissue useful as tissue grafts**

**12/26, TI/4 (Item 4 from file: 350)**

DIALOG(R)File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.  
011960343

WPI Acc No: 1998-377253/199832

**Composition comprising liver basement membrane free of vertebrate cells - is useful in replacing or repairing damaged tissues, or in promoting in vitro cell growth**

**12/26, TI/5 (Item 5 from file: 350)**

DIALOG(R)File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.  
011960342

WPI Acc No: 1998-377252/199832

**Composition comprising stomach submucosal tissue - may used to promote growth of endogenous tissue, e.g. connective tissue, or to enhance in vitro growth of cells**

**12/26, TI/6 (Item 6 from file: 350)**

DIALOG(R)File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.  
011931546

Serial 09/857307

August 13, 2003

WPI Acc No: 1998-348456/199830

**Preparation of bioactive extracts useful, e.g. in wound healing - by extracting sub-mucosal tissue with aqueous solution of extraction excipients, e.g. chaotropic agents, enzymes or enzyme inhibitor(s)**

**12/26, TI/7 (Item 7 from file: 350)**

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

011535891

WPI Acc No: 1997-512372/199747

**Perforated submucosal tissue grafts constructs - has multiple strips of intestinal submucosa having planar surfaces delimited from both tunica muscularis with perforation defining longitudinal axis**

**12/26, TI/8 (Item 8 from file: 350)**

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

010967817

WPI Acc No: 1996-464766/199646

**Tissue graft for repair of damaged or diseased urinary tract - uses sub-mucosal tissue of warm blooded vertebrate**

**12/26, TI/9 (Item 9 from file: 350)**

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

010967813

WPI Acc No: 1996-464762/199646

**Making large area submucosal grafts - by fusing partially overlapped strips of tissue by compression under dehydrating conditions**

**12/26, TI/10 (Item 10 from file: 350)**

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

010927668

WPI Acc No: 1996-424619/199642

**Graft compsn. for inducing formation of endogenous connective tissue - comprising urinary bladder submucosa obtained from e.g. cattle, sheep or pigs**

**12/26, TI/11 (Item 11 from file: 350)**

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

010896190

WPI Acc No: 1996-393141/199639

**Transformation of eukaryotic cells, partic. in vivo - using exogenous nucleic acid sequence and sub-mucosal tissue of warm-blooded vertebrate**

**12/26, TI/12 (Item 12 from file: 350)**

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

010887264

WPI Acc No: 1996-384215/199638

**Bone graft compsn. prep'd. from intestinal submucosa tissue - useful in e.g. filling or bridging bone defects and assisting repair of high-risk fractures and attachment of prostheses and treating periodontal diseases**

**12/26, TI/13 (Item 13 from file: 350)**

Serial 09/857307

August 13, 2003

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

010835686

WPI Acc No: 1996-332639/199633

Prodn. of tissue graft compsns. from intestinal tissue of warm-blooded vertebrate - by comminution or protease digestion of intestinal sub-mucosal tissue, promote wound healing and induce formation of endogenous tissue in vivo

12/26, TI/14 (Item 14 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

010048428

WPI Acc No: 1994-316139/199439

New tissue graft constructs - comprise sheet of intestine of warm-blooded vertebrate and comminuted or protease-digested intestine

12/26, TI/15 (Item 15 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

009736162

WPI Acc No: 1994-016012/199402

Fluidised intestinal submucosa prep. - by comminuting intestinal tissue and hydrating, useful for tissue repair or tissue reconstruction

12/26, TI/16 (Item 16 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

009423726

WPI Acc No: 1993-117242/199314

Graft for promoting autogenous tissue growth - formed from delaminated segment of stretched intestinal tissue

12/26, TI/17 (Item 17 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

008164578

WPI Acc No: 1990-051579/199007

Tissue graft compsn. of intestine segment - with tunica submucosa and muscularis mucosa and luminal part of tunica mucosa removed

File 348:EUROPEAN PATENTS 1978-2003/Jul W03

File 349:PCT FULLTEXT 1979-2002/UB=20030807,UT=20030731

Set	Items	Description
S1	49	AU='BADYLAK STEPHEN F' OR AU='BADYLAK STEPHEN FRANCIS'
S2	11	AU='SPIEVACK ALAN R'
<b>S3</b>	<b>2</b>	<b>S1 AND S2 [duplicates]</b>
S4	4543	SUBMUCOSA? OR BASEMENT() MEMBRANE
S5	41	(S1:S2 AND S4) NOT S3
S6	41	IDPAT (sorted in duplicate/non-duplicate order)
<b>S7</b>	<b>27</b>	<b>IDPAT (primary/non-duplicate records only)</b>

7/3,AB,K/2 (Item 4 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00568836

**SUBMUCOSA MODULATION OF MAMMALIAN IMMUNE RESPONSE****MODULATION SOUS-MUQUEUSE DE LA REPONSE IMMUNITAIRE CHEZ UN MAMMIFERE**

Patent Applicant/Assignee:

PURDUE RESEARCH FOUNDATION,  
 MEDICAL COLLEGE OF OHIO AT TOLEDO,  
 BADYLAK Stephen F,  
 McPHERSON Timothy B,  
 METZGER Dennis,

Inventor(s):

BADYLAK Stephen F,  
 McPHERSON Timothy B,  
 METZGER Dennis,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200032209 A2 20000608 (WO 0032209)  
 Application: WO 99US28302 19991201 (PCT/WO US9928302)  
 Priority Application: US 98110402 19981201

Designated States: AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK  
 DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR  
 LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ  
 TM TR TT TZ UA UG US UZ VN YU ZA ZW GH GM KE LS MW SD SL SZ TZ UG ZW AM  
 AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL  
 PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 9591

English Abstract

A composition and method for locally suppressing the cell mediated immune response of a vertebrate species is described. The method comprises contacting the site in need of immune suppression with a composition comprising vertebrate submucosa.

Fulltext Availability:

Detailed Description

Detailed Description

... groups for this model are described in the Table 2. On the specified day following **submucosa implantation**, the animals were sensitized by application of 20 pl of 0.5% dinitrofluorobenzene (DNFB; Sigma...)

...1) to the shaved abdomen. Five days after sensitization with DNFB, the thickness of each **ear** of each animal were measured using a spring-loaded caliper (Mitutoyo). One **ear** was then challenged with 20 **tl** of 0.2% DNFB while the other **ear** was left untreated. The thickness of each **ear** was measured again after 24 hours. The ratio of

post-challenge to pre-challenge thickness was calculated for each **ear**.

Table 2. Experimental Groups for Contact Den-natititis Assay

**Sensitize Challenge**

Group Strain n Treatment...strain specific responses do not appear to have confounded the analysis of the effect of **submucosa implantation**.

In summary, the exposure to **submucosa** does not cause predisposition to infection or other immune insufficiency due to the Th2 dominant...

...or the other type. Similarly, the contact derniatitis model showed suppression of the intensity of **ear** swelling response, but the expected normal response was present and significantly greater than non-treated...

**7/TI/1 (Item 1 from file: 348)**

DIALOG(R)File 348:(c) 2003 European Patent Office. All rts. reserv.

**Stomach submucosa derived tissue graft**

**7/TI/3 (Item 3 from file: 348)**

DIALOG(R)File 348:(c) 2003 European Patent Office. All rts. reserv.

**ENHANCED SUBMUCOSAL TISSUE GRAFT CONSTRUCTS**

**7/TI/4 (Item 4 from file: 348)**

DIALOG(R)File 348:(c) 2003 European Patent Office. All rts. reserv.

**GALACTOSIDASE MODIFIED SUBMUCOSAL TISSUE**

**7/TI/5 (Item 5 from file: 348)**

DIALOG(R)File 348:(c) 2003 European Patent Office. All rts. reserv.

**SUBMUCOSA EXTRACTS**

**7/TI/6 (Item 6 from file: 348)**

DIALOG(R)File 348:(c) 2003 European Patent Office. All rts. reserv.

**TUBULAR SUBMUCOSAL GRAFT CONSTRUCTS**

**7/TI/7 (Item 7 from file: 348)**

DIALOG(R)File 348:(c) 2003 European Patent Office. All rts. reserv.

**STOMACH SUBMUCOSA DERIVED TISSUE GRAFT**

**7/TI/8 (Item 8 from file: 348)**

DIALOG(R)File 348:(c) 2003 European Patent Office. All rts. reserv.

**GASTRIC SUBMUCOSAL TISSUE AS A NOVEL DIAGNOSIS TOOL**

**7/TI/9 (Item 9 from file: 348)**

DIALOG(R)File 348:(c) 2003 European Patent Office. All rts. reserv.

**PERFORATED SUBMUCOSAL TISSUE GRAFT CONSTRUCTS**

**7/TI/10 (Item 10 from file: 348)**

DIALOG(R)File 348:(c) 2003 European Patent Office. All rts. reserv.

**LARGE AREA SUBMUCOSAL GRAFT CONSTRUCTS AND METHOD FOR MAKING THE SAME**

**7/TI/12 (Item 12 from file: 348)**

DIALOG(R)File 348:(c) 2003 European Patent Office. All rts. reserv.

**URINARY BLADDER SUBMUCOSA DERIVED TISSUE GRAFT**

**7/TI/13 (Item 13 from file: 348)**

DIALOG(R)File 348:(c) 2003 European Patent Office. All rts. reserv.

**SUBMUCOSA AS A GROWTH SUBSTRATE FOR CELLS**

**7/TI/15 (Item 15 from file: 348)**

Serial 09/857307

August 13, 2003

DIALOG(R)File 348:(c) 2003 European Patent Office. All rts. reserv.  
**FLUIDIZED INTESTINAL SUBMUCOSA AND ITS USE AS AN INJECTABLE TISSUE GRAFT**

**7/TI/16 (Item 16 from file: 348)**

DIALOG(R)File 348:(c) 2003 European Patent Office. All rts. reserv.  
**GRAFT FOR PROMOTING AUTOGENOUS TISSUE GROWTH**

**7/TI/18 (Item 18 from file: 349)**

DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.  
**BIOMATERIAL DERIVED FROM VERTEBRATE LIVER TISSUE**

**7/TI/20 (Item 20 from file: 349)**

DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.  
**TISSUE REGENERATIVE COMPOSITION**

**7/TI/21 (Item 21 from file: 349)**

DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.  
**BIOMATERIAL DERIVED FROM VERTEBRATE LIVER TISSUE**

**7/TI/22 (Item 22 from file: 349)**

DIALOG(R)File 349:(c) 2003 WIPO/Univentio. All rts. reserv.  
**STOMACH SUBMUCOSA DERIVED TISSUE GRAFT**

Serial 09/857307

August 13, 2003

File 155: MEDLINE(R) 1966-2003/Aug W2  
 File 5: Biosis Previews(R) 1969-2003/Aug W1  
 File 73: EMBASE 1974-2003/Aug W1  
 File 34: SciSearch(R) Cited Ref Sci 1990-2003/Aug W1  
 File 434: SciSearch(R) Cited Ref Sci 1974-1989/Dec

Set	Items	Description
S1	530	AU='BADYLAK S' OR AU='BADYLAK S F':AU='BADYLAK STEVEN F'
S2	19	AU='SPIEVACK A' OR AU='SPIEVACK A R':AU='SPIEVACK AR'
S3	7	S1 AND S2
S4	3	<b>RD (unique items) [too recent]</b>
S5	159433	SUBMUCOSA? OR (BASEMENT OR HYALINE) () MEMBRANE? OR (BASAL OR BASEMENT) () LAMINA
S6	535	S1:S2 NOT S3
S7	223	S5 AND S6
S8	29	S7/1999 OR S7/2000
S9	58	S7/2001 OR S7/2002
S10	4	S7/2003
S11	132	S7 NOT S8:S10
S12	54	RD (unique items)
S13	584064	VOCAL()CORD? ? OR LARYNX OR LARYNGE? OR PALAT?? OR NASAL OR NOSE OR AURICULA?? OR EAR OR EARS
S14	0	S12 AND S13
S15	4816595	SURGICAL? OR SURGERY OR SURGERIES
S16	30	S12 AND S15
S17	628113	HEAD OR NECK
S18	0	S16 AND S17
S19	0	S8:S10 AND S13
S20	0	S8:S10 AND S17
S21	34	S8:S10 AND S15
S22	30	<b>Sort S16/ALL/PY,D</b>

22/6/4 (Item 4 from file: 155)

11680598 99115999 PMID: 9916170

Small intestinal submucosa : a rapidly resorbed bioscaffold for augmentation cystoplasty in a dog model.

Winter 1998

22/6/5 (Item 5 from file: 155)

11510336 98397802 PMID: 9730065

Multilaminate resorbable biomedical device under biaxial loading.

Fall 1998

22/6/9 (Item 9 from file: 155)

10681616 97030781 PMID: 8876722

Histology after dural grafting with small intestinal submucosa .

Oct 1996

22/6/10 (Item 10 from file: 155)

10479977 96289399 PMID: 8683741

Characterization of small intestinal submucosa regenerated canine detrusor: assessment of reinnervation, in vitro compliance and contractility.

Aug 1996

22/6/12 (Item 12 from file: 5)

10397427 BIOSIS NO.: 199699018572

Small-intestinal submucosa as a replacement graft for defects of the

**tunica albuginea in rats.**  
1996

22/6/15 (Item 15 from file: 155)  
10292710 96094591 PMID: 7490890

**Detrusor regeneration in the rat using porcine small intestinal submucosal grafts: functional innervation and receptor expression.**

Jan 1996

22/9/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

13480579 BIOSIS NO.: 200200109400

**Perforated submucosal tissue graft constructs.**

AUTHOR: Whitson B; Cheng B; **Badylak S F**

AUTHOR ADDRESS: West Lafayette, Ind.\*\*USA

JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1210 (4):p3402 May 26, 1998

PATENT NUMBER: US 5755791 PATENT DATE GRANTED: May 26, 1998 19980526

PATENT ASSIGNEE: METHODIST HOSPITAL OF INDIANA; PURDUE RESEARCH FOUNDATION

PATENT COUNTRY: USA

ISSN: 0098-1133

DOCUMENT TYPE: Patent

RECORD TYPE: Citation

LANGUAGE: English

MAJOR CONCEPTS: Digestive System (Ingestion and Assimilation); Methods and Techniques; **Surgery** (Medical Sciences)

MISCELLANEOUS TERMS: BIOTECHNOLOGY; MULTIPLE INTESTINAL **SUBMUCOSA** STRIPS

CONCEPT CODES:

14001 Digestive System-General; Methods

11107 Anatomy and Histology, General and Comparative-Regeneration and Transplantation (1971- )

01004 Methods, Materials and Apparatus, General-Laboratory Methods

22/9/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

13473576 BIOSIS NO.: 200200102397

**Large area submucosal tissue graft constructs.**

AUTHOR: Patel U H; Hiles M C; Whitson B; Cheng B; **Badylak S F**; Kokini K

AUTHOR ADDRESS: W. Lafayette, Ind.\*\*USA

JOURNAL: Official Gazette of the United States Patent and Trademark Office  
Patents 1206 (4):p2878-2879 Jan. 27, 1998

PATENT NUMBER: US 5711969 PATENT DATE GRANTED: Jan. 27, 1998 19980127

PATENT ASSIGNEE: METHODIST HOSPITAL OF INDIANA; PURDUE RESEARCH FOUNDATION

PATENT COUNTRY: USA

ISSN: 0098-1133

DOCUMENT TYPE: Patent

RECORD TYPE: Citation

LANGUAGE: English

MAJOR CONCEPTS: Digestive System (Ingestion and Assimilation); Methods and Techniques; **Surgery** (Medical Sciences)

MISCELLANEOUS TERMS: BIOTECHNOLOGY; FUSION; INTESTINAL **SUBMUCOSA** TISSUE

CONCEPT CODES:

14001 Digestive System-General; Methods  
11107 Anatomy and Histology, General and Comparative-Regeneration and  
Transplantation (1971- )  
01004 Methods, Materials and Apparatus, General-Laboratory Methods

**22/9/8 (Item 8 from file: 5)**

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

13414640 BIOSIS NO.: 200200043461

**Fluidized intestinal submucosa and its use as an injectable tissue graft**

AUTHOR: **Badylak, S F**; Demeter R J; Hiles M; Voytik S; Knapp P M Jr

AUTHOR ADDRESS: West Lafayette, Ind.\*\*USA

JOURNAL: Official Gazette of the United States Patent and Trademark Office

Patents 1186 (2):p1141 May 14, 1996

PATENT NUMBER: US 5516533 PATENT DATE GRANTED: May 14, 1996 19960514

PATENT ASSIGNEE: METHODIST HOSPITAL OF INDIANA, INC.; PURDUE RESEARCH

FOUNDATION PATENT COUNTRY: USA

ISSN: 0098-1133

DOCUMENT TYPE: Patent

RECORD TYPE: Citation

LANGUAGE: English

MAJOR CONCEPTS: Digestive System (Ingestion and Assimilation); Methods and Techniques; Pharmacology; **Surgery** (Medical Sciences)

MISCELLANEOUS TERMS: HEALTH CARE; PHARMACEUTICALS; TRANSPLANTATION

CONCEPT CODES:

14001 Digestive System-General; Methods  
22002 Pharmacology-General  
11107 Anatomy and Histology, General and Comparative-Regeneration and  
Transplantation (1971- )  
01004 Methods, Materials and Apparatus, General-Laboratory Methods

Serial 09/857307

August 13, 2003

File 155: MEDLINE(R) 1966-2003/Aug W2

Set	Items	Description
S1	3902	'VOCAL CORDS' OR DC='A4.329.364.737.' OR 'VOCAL FOLD'
S2	777	'VOCAL CORDS --SURGERY --SU'
S3	15554	'BASEMENT MEMBRANE' OR DC='A10.272.220.' OR DC='A10.615.17-9.' OR 'BASAL LAMINA' OR 'BASEMENT LAMINA' OR 'BRUCH MEMBRANE'
S4	26633	'LARYNX' OR DC='A4.329.' OR 'ARYTENOID CARTILAGE' OR 'CRICOID CARTILAGE' OR 'EPIGLOTTIS' OR 'GLOTTIS' OR 'GOBLET CELLS' OR 'LARYNGEAL CARTILAGES' OR 'LARYNGEAL MUCOSA' OR 'LARYNGEAL MUSCLES' OR 'THYROID CARTILAGE' OR 'VOCAL CORDS'
S5	23197	'PALATE' OR DC='A14.521.658.' OR DC='A14.549.617.' OR 'INCISIVE PAPILLA' OR 'PALATAL MUSCLES' OR 'PALATE, HARD' OR 'PALATE, SOFT' OR 'UVULA'
S6	548	'HEAD --SURGERY --SU'
S7	1831	'NECK --SURGERY --SU'
S8	3806	SUBMUCOSA
S9	19327	S3 OR S8
S10	51235	S1:S2 OR S4:S7
S11	183	S9 AND S10
S12	941956	SURGERY/DE OR SU/DE
S13	15	S11 AND S12
S14	15	RD (unique items)
S15	5	S14/1999:2003
S16	10	S14 NOT S15
S17	10	Sort S16/ALL/PY,D
S18	0	S6:S7 AND S11
S19	495601	GRAFT? ? OR HOMOGRAFT? ? OR HETEROGRAFT? ? OR TRANSPLANT? - OR IMPLANT?
S20	8	S11 AND S19
S21	3	S20 NOT S13 [too recent]
S22	5	S20 NOT S21 [some duplicates; some not relevant]

17/6/1

11374781 98255728 PMID: 9596289

Radiofrequency volumetric tissue reduction of the palate in subjects with sleep-disordered breathing.

May 1998

17/6/2

10829042 97180078 PMID: 9028293

Clinical evaluation of an acellular dermal allograft for increasing the zone of attached gingiva.

Mar 1996

17/6/5

07872043 93327728 PMID: 8334965

Tracheobronchopathia osteochondroplastica: a case report and a review of the literature.

May 1993

17/6/7

05931813 88286230 PMID: 3165120

Hydroxylapatite as a bone graft substitute in orthognathic surgery: histologic and histometric findings.

Aug 1988

17/9/6

Serial 09/857307

August 13, 2003

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

07057145 91298029 PMID: 2068929

**A new concept for reconstruction of atresias of larynx and trachea: lining of wound surfaces with autologous isolated respiratory epithelial cells.**Gerhardt H J; Bohm K; Kaschke O; Biedermann F  
ENT Clinic, University Hospital (Charite), Humboldt University, Berlin, Germany.

Acta oto-laryngologica (SWEDEN) 1991, 111 (2) p410-3, ISSN 0001-6489 Journal Code: 0370354

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

A new method, first applied two years ago in our clinic, has proved to be reliable for achieving a rapid reepithelialisation of epithelial defects after scar removal inside the trachea. The defect is seeded with isolated respiratory epithelial cells harvested the day before from the ethmoid. Isolation of epithelial cells was achieved by keeping the mucosa in 0.25% trypsin buffer solution under room temperature for about 16 h. Afterwards, the epithelial layer was separated from the **submucosa** using small forceps and knife. Cells were then isolated by pipetting. For seeding the wound the surface was covered with silastic sheeting and the cell suspension then injected into the cleft between both of them. Cell distribution occurred by capillary attraction. The tracheal lumen was maintained by inserting a silastic stent for about three weeks. So far, 10 patients between 6 and 45 years have been treated in this way. In 4 patients the tracheal wall additionally had to be stabilized using rip cartilage. Only in one case above the tracheostoma, considerable scar formation occurred again requiring a second operation some months later. In 8 patients decannulation was meanwhile possible.

Tags: Case Report; Human; Male

Descriptors: **Larynx -- surgery -- SU ; \*Trachea-- surgery -- SU ; \*Wound Healing; Adolescent; Adult; Cell Separation; Child; Epithelial Cells; Epithelium--transplantation--TR; Ethmoid Sinus--cytology--CY; Larynx --abnormalities--AB; Methods; Middle Age; Mucous Membrane--cytology--CY; Mucous Membrane--transplantation--TR; Silicone Elastomers; Trachea --abnormalities--AB; Trachea--cytology--CY**

CAS Registry No.: 0 (Silicone Elastomers)

Record Date Created: 19910813

Record Date Completed: 19910813

17/9/8

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

05458146 87136799 PMID: 3546221

**Dilatation of the glottis in bilateral vocal cord paralysis. Review of various surgical procedures and a report of personal experience using a functional lateral fixation surgical technique]**

Glottiserweiterung bei beidseitiger Stimmlippenlähmung. Ein Überblick über die verschiedenen Operationsverfahren und ein Erfahrungsbericht über eine persönliche Operationstechnik "Die funktionelle Lateralfixation".

Schobel H

HNO (GERMANY, WEST) Dec 1986, 34 (12) p485-95, ISSN 0017-6192

Journal Code: 2985099R

Document type: Journal Article ; English Abstract

Languages: GERMAN

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

For the treatment of bilateral vocal cord paralysis, the author's technique consists of preservation of the posterior crico-arytenoid ligament as a hinge as well as turning and tilting of the arytenoid cartilage laterally. It is held in this position with three permanent retention sutures, two of them armed with heavy knots. These knots will reinforce the lateral rotation of the arytenoid cartilage. These sutures run in the **submucosa** horizontally along the anterior surface of the arytenoid cartilage and are fixed through burr holes on the posterior margin of the thyroid cartilage. This method developed from the original "King Procedure" leaves the laryngeal mucosa maximally undisturbed so that in 80% of the cases preliminary tracheotomy became unnecessary. During a period of 27 years, 110 patients were operated; 27 of them had a previously created tracheostoma. Out of the remaining 83, 16 had tracheotomy directly before surgery. Of the remaining 67 patients, four required postoperative tracheotomy for a few days only, while 63 did not require this additional treatment. The average hospital stay was 11 days. In the majority of cases the operation could be performed under local anaesthesia which helped to establish proper voice function.

Tags: Human

Descriptors: Vocal Cord Paralysis--**surgery**--SU; Adolescent; Adult; Aged; Aged, 80 and over; Airway Obstruction--**surgery**--SU; Child; Child, Preschool; Dilatation--methods--MT; Follow-Up Studies; Laryngeal Cartilages--**surgery**--SU; Laryngeal Mucosa--**surgery**--SU; Middle Age; Suture Techniques; Tracheotomy--methods--MT; Vocal Cords--**surgery**--SU

Record Date Created: 19870330

Record Date Completed: 19870330

17/9/9

DIALOG(R) File 155: MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

05321277 86322662 PMID: 3753294

**A personal experience with subtotal and conservation surgery as treatment for laryngeal cancer.**

Callearo C; Bignardi L

Archives of oto-rhino-laryngology (GERMANY, WEST) 1986, 243 (3)  
p174-9, ISSN 0302-9530 Journal Code: 0414105

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Subfile: INDEX MEDICUS

A personal technique for laryngeal cancer reconstructive surgery is presented and discussed. The functional and therapeutic purpose of this surgery is to broaden its indications and to improve functional results. In particular, our surgical technique involves removal of the soft internal part of the cricoid cartilage (mucosa, **submucosa** and perichondrium), which is otherwise conserved. Satisfactory functional results can be achieved by: modeling of two symmetrical pseudoarytenoids; an anterior epiglottoplasty or the use of a Hiranandani base-of-the-tongue flap to close the anterior gap (if present); muscular flap lateral-plasty avoiding a cricoidhyoidpexy.

Tags: Human

Descriptors: **Cricoid Cartilage -- surgery -- SU ; \* Laryngeal Cartilages -- surgery -- SU ; \*Laryngeal Neoplasms-- surgery -- SU ; \*Laryngectomy--methods--MT; Laryngeal Muscles -- surgery -- SU ; Thyroid Cartilage -- surgery -- SU ; Tracheotomy--methods--MT**

Record Date Created: 19860926

Record Date Completed: 19860926

Serial 09/857307

August 13, 2003

File 5:Biosis Previews(R) 1969-2003/Aug W1  
File 73:EMBASE 1974-2003/Aug W1  
File 34:SciSearch(R) Cited Ref Sci 1990-2003/Aug W1  
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec  
File 144:Pascal 1973-2003/Aug W1  
File 94:JICST-EPlus 1985-2003/Aug W1  
File 95:TEME-Technology & Management 1989-2003/Jul W4  
File 99:Wilson Appl. Sci & Tech Abs 1983-2003/Jun  
File 65:Inside Conferences 1993-2003/Aug W2  
File 35:Dissertation Abs Online 1861-2003/Jul  
File 6:NTIS 1964-2003/Aug W2  
File 8:Ei Compendex(R) 1970-2003/Aug W1  
Set Items Description  
S1 140822 SUBMUCOSA? ? OR (BASEMENT OR HYALINE) () MEMBRANE? ? OR (BAS-  
AL OR BASEMENT) () LAMINA? ?  
S2 167222 VOCAL() (CORD? ? OR FOLD? ?) OR LARYNX OR LARYNGE? OR PALAT-  
E? ? OR PALATAL  
S3 425583 NASAL OR NOSE OR AURICULA? ? OR EAR OR EARS  
S4 3614 (HEAD OR NECK) (2N) TISSUE  
S5 673302 GRAFT? OR HOMOGRAFT? OR HETEROGRAFT? OR ALLOGRAFT? OR AUTO-  
GRAFT?  
S6 2077781 IMPLANT? OR TRANSPLANT?  
S7 6048 S1(S)S5:S6  
S8 151 S7 AND S2:S4  
S9 392262 S2:S4/TI,DE  
S10 76 S8 AND S9  
S11 52 RD (unique items)  
S12 10 S11/1999:2003  
S13 42 S11 NOT S12  
S14 42 Sort S13/ALL/PY, D  
S15 76 S8(S)S9  
S16 42 S15 AND S14  
S17 841 S7/TI,DE  
S18 4 S16 AND S17  
S19 38 S14 NOT S18  
S20 1227 S1(3N)S5:S6  
S21 6 S19 AND S20  
S22 32 S19 NOT S21  
S23 32 Sort S22/ALL/PY, D  
S24 2418512 SURGERY/DE OR SURGICAL OR SU/DE  
S25 16 S23 AND S24  
S26 16 S23 NOT S25

18/6/3 (Item 3 from file: 5)

03599860 BIOSIS NO.: 000074015437

SUBMUCOSAL NASAL SEPTUM RESECTION WITH AUTO RE IMPLANTATION OF  
CARTILAGE AND BONE IN RECURRENT NASAL BLEEDING IN THE PRESENCE OF  
HYPERTENSIVE DISEASE

1981

18/6/4 (Item 1 from file: 73)

00215465 EMBASE No: 1974205634

Submucosal septal resection followed by immediate reconstruction by  
bone grafting

1974

Serial 09/857307

August 13, 2003

18/9/2 (Item 2 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

06295884 BIOSIS NO.: 000086130067

**SURGERY FOR BILATERAL NASAL VALVULAR COLLAPSE**

AUTHOR: OCHI J W; DEWERD D L

AUTHOR ADDRESS: DIV. HEAD AND NECK SURGERY, UCSD MED. CENT., 225 DICKINSON ST., SAN DIEGO, CALIF. 92103, USA.

JOURNAL: RHINOLOGY (ROTT) 26 (2). 1988. 105-110. 1988

FULL JOURNAL NAME: RHINOLOGY (Rotterdam)

CODEN: RNGYA

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: The **nasal** valve is an important regulator of **nasal** airflow.

Patients may suffer from **nasal** obstruction due to bilateral **nasal** valvular collapse combined with a drooping tip. A simple, effective technique of cartilage **grafting** to open the valve is forwarded. The advantages of this method include placing the **graft** in the **submucosal** plane which preserves mucosa and protects the **graft** from **nasal** secretions while healing.

DESCRIPTORS: HUMAN **NASAL** AIRFLOW CARTILAGE **GRAFTING** **SUBMUCOSAL** PLANE

## CONCEPT CODES:

11105 Anatomy and Histology, General and Comparative-Surgery

12512 Pathology, General and Miscellaneous-Therapy (1971- )

16002 Respiratory System-Anatomy

16006 Respiratory System-Pathology

18001 Bones, Joints, Fasciae, Connective and Adipose Tissue-General; Methods

18006 Bones, Joints, Fasciae, Connective and Adipose Tissue-Pathology

16001 Respiratory System-General; Methods

## BIOSYSTEMATIC CODES:

86215 Hominidae

## BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA):

Animals

Chordates

Vertebrates

Mammals

Primates

Humans

21/9/1 (Item 1 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

09160984 BIOSIS NO.: 199497169354

**Fundamental frequency and amplitude perturbation in reconstructed canine vocal folds.**

AUTHOR: Jiang Jack J; Titze Ingo R(a); Wexler David B; Gray Steven D

AUTHOR ADDRESS: (a) Dep. Speech Pathology and Audiology, The University Iowa, Iowa City, IA 52242\*\*USA

JOURNAL: Annals of Otology Rhinology &amp; Laryngology 103 (2):p145-148 1994

ISSN: 0003-4894

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: A **submucosal** fat autograft was **implanted** within the cover of injured **vocal folds** of 5 dogs. The **implant** occurred 6 weeks

after unilateral mucosal excision had been performed. Three months postoperatively the **larynges** of these animals were excised and their phonation was compared to that of normal dog **larynges** and to other **larynges** with mucosal excision (but without fat **grafting**). Radiated acoustic pressure from the artificially driven **larynges** was recorded and digitized at 20 kHz with 16-bit resolution. Amplitude and fundamental frequency perturbations were extracted from a segment of phonation to assess the stability of the acoustic signals from the 3 groups. It was found that fat augmentation after mucosal excision reduced amplitude and frequency perturbation measures. There was no significant difference between fat-augmented and normal **vocal folds**. The acoustic measures were also positively correlated with phonation threshold and phonation efficiency measures reported earlier. The results suggest that **submucosal fat autograft implantation** within an injured **vocal fold** cover can restore not only the "ease" of phonation, but also the stability of phonation, which is a component of vocal quality.

DESCRIPTORS:

MAJOR CONCEPTS: Dental and Oral System (Ingestion and Assimilation);  
Physiology

BIOSYSTEMATIC NAMES: Canidae--Carnivora, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: Canidae (Canidae)

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): animals; carnivores; chordates; mammals; nonhuman vertebrates; nonhuman mammals; vertebrates

MISCELLANEOUS TERMS: ACOUSTIC MEASUREMENTS; AUTOGRAPH; FUNDAMENTAL FREQUENCY; PHONATION

CONCEPT CODES:

11107 Anatomy and Histology, General and Comparative-Regeneration and Transplantation (1971- )

19004 Dental and Oral Biology-Physiology and Biochemistry

11105 Anatomy and Histology, General and Comparative-Surgery

BIOSYSTEMATIC CODES:

85765 Canidae

21/9/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

07276820 BIOSIS NO.: 000090056707

THE BEHAVIOR OF ALLOPLASTIC TYMPANIC MEMBRANES IN STAPHYLOCOCCUS-AUREUS-INDUCED MIDDLE EAR INFECTION II. MORPHOLOGICAL STUDY OF EPITHELIAL REACTIONS

AUTHOR: BAKKER D; VAN BLITTERSWIJK C A; HESSELING S C; DAEMS W T; GROTE J J

AUTHOR ADDRESS: EAR NOSE AND THROAT DEP., UNIVERSITY HOSP., THE NETHERLANDS.

JOURNAL: J BIOMED MATER RES 24 (7). 1990. 809-828. 1990

FULL JOURNAL NAME: Journal of Biomedical Materials Research

CODEN: JBMRB

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: Epithelial reactions to Silastic, Estane polyether urethane, polypropylene oxide, and a poly(ethylene oxide hydantoin) and poly(tetramethylene terephthalate) segmented polyether polyester copolymer were investigated after **implantation** in tympanic membranes and **submucosa** of noninfected and *Staphylococcus aureus*-infected rat middle ears. Porous **implants** made of Estane and polypropylene oxide were completely covered by tympanic-membrane connective tissue, epidermis, and epithelium in 2 weeks and those made of copolymer in

between 2 and 4 weeks postoperatively. Silastic **implants**, which were dense, were not enveloped by tympanic-membrane tissue but rejected. Starting in the 6th postoperative month the proliferative-activity and structure of both the tympanic membrane epithelium and epidermis became normal except for the presence of iron-containing secretory epithelium near polypropylene oxide. After initial swelling caused by the surgical trauma, neither the proliferative activity nor the composition of the epithelium covering **submucosal implants** was affected by the presence of any of the biomaterials. Infection of middle **ears** bearing **implants** induced epithelial reactions similar to those associated with infected middle **ears** without an **implant**.

DESCRIPTORS: BACTERIA RAT MAMMAL PROSTHETIC BIOMEDICAL INSTRUMENTATION

IMPLANT

CONCEPT CODES:

- 10506 Biophysics-Molecular Properties and Macromolecules
- 10508 Biophysics-Membrane Phenomena
- 10511 Biophysics-Bioengineering
- 11105 Anatomy and Histology, General and Comparative-Surgery
- 11107 Anatomy and Histology, General and Comparative-Regeneration and Transplantation (1971- )
- 20006 Sense Organs, Associated Structures and Functions-Pathology
- 20008 Sense Organs, Associated Structures and Functions-Deafness, Speech and Hearing
- 36002 Medical and Clinical Microbiology-Bacteriology
- 02506 Cytology and Cytochemistry-Animal
- 11108 Anatomy and Histology, General and Comparative-Microscopic and Ultramicroscopic Anatomy

BIOSYSTEMATIC CODES:

- 05510 Micrococcaceae (1979- )
- 86375 Muridae

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA):

- Microorganisms
- Bacteria
- Animals
- Chordates
- Vertebrates
- Nonhuman Vertebrates
- Mammals
- Nonhuman Mammals
- Rodents

21/9/3 (Item 3 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

06816145 BIOSIS NO.: 000088125589

**PHONOSURGICAL STUDIES FAT-GRAFT RECONSTRUCTION OF INJURED CANINE VOCAL CORDS**

AUTHOR: WEXLER D B; JIANG J; GRAY S D; TITZE I R

AUTHOR ADDRESS: DEP. OTOLARYNGOL., HEAD NECK SURGERY, UNIV. IOWA HOSP. CLINICS, IOWA CITY, IA 52242.

JOURNAL: ANN OTOL RHINOL LARYNGOL 98 (9). 1989. 668-673. 1989

FULL JOURNAL NAME: Annals of Otology Rhinology & Laryngology

CODEN: AORHA

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: Damage to the **vocal cords** can result in scarring and impaired

vibration and can manifest clinically as hoarseness and loss of vocal power. If the vibratory characteristics could be restored in these scarred **vocal cords**, the vocal intensity and efficiency of phonation also should improve. In an effort to enhance the vibration of damaged **vocal cords**, we **implanted** a **submucosal** fat **autograft** within the injured **vocal cord** cover layer of dogs 6 weeks after unilateral mucosal excision had been performed. Three months postoperatively these animals were compared to normal dogs and those with mucosal excision but no fat- **grafting**. Acoustic and biomechanical measures of phonation were collected from an excised **larynx** preparation. We found that the fat-augmented **vocal cords** had lower threshold pressures for phonation, greater vocal intensity, and more efficient acoustic output than injured **vocal cords** without the fat- **grafting**. These results provide a foundation for further research on reconstructive surgery of damaged **vocal cords**.

DESCRIPTORS: HOARSENESS LOSS OF VOCAL POWER WOUND HEALING

CONCEPT CODES:

- 11107 Anatomy and Histology, General and Comparative-Regeneration and Transplantation (1971- )
- 12504 Pathology, General and Miscellaneous-Diagnostic
- 12508 Pathology, General and Miscellaneous-Inflammation and Inflammatory Disease
- 12512 Pathology, General and Miscellaneous-Therapy (1971- )
- 20006 Sense Organs, Associated Structures and Functions-Pathology
- 20008 Sense Organs, Associated Structures and Functions-Deafness, Speech and Hearing
- 10066 Biochemical Studies-Lipids
- 11105 Anatomy and Histology, General and Comparative-Surgery
- 20001 Sense Organs, Associated Structures and Functions-General; Methods

BIOSYSTEMATIC CODES:

- 85765 Canidae

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA):

- Animals
- Chordates
- Vertebrates
- Nonhuman Vertebrates
- Mammals
- Nonhuman Mammals
- Carnivores

21/9/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

06039017 BIOSIS NO.: 000085002166

#### A COMPREHENSIVE REPAIR OF UNILATERAL CLEFT LIP IN ADULTS

AUTHOR: KUMAR P A V

AUTHOR ADDRESS: DEP. PLASTIC SURG., JAWAHARLAL INST. POSTGRADUATE MED.

EDUC. RES., PONDICHERRY, PIN. 605006, INDIA.

JOURNAL: BR J PLAST SURG 40 (5). 1987. 478-484. 1987

FULL JOURNAL NAME: British Journal of Plastic Surgery

CODEN: BJPSA

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: A comprehensive operation for primary repair of adult cleft lip is described. The technique employs pyriform fossa bone **graft**, **submucosal**

resection of the **nasal** septum and alar cartilage onlay **graft** in addition to a modified rotation advancement with refinements. Good results were obtained in 70% of the cases with no increase in morbidity.

DESCRIPTORS: HUMAN BONE GRAFT **NASAL** SEPTUM

CONCEPT CODES:

- 11107 Anatomy and Histology, General and Comparative-Regeneration and Transplantation (1971- )
- 12512 Pathology, General and Miscellaneous-Therapy (1971- )
- 18001 Bones, Joints, Fasciae, Connective and Adipose Tissue-General; Methods
- 19001 Dental and Oral Biology-General; Methods
- 19006 Dental and Oral Biology-Pathology
- 25552 Developmental Biology-Embryology-Descriptive Teratology and Teratogenesis
- 11105 Anatomy and Histology, General and Comparative-Surgery
- 11306 Chordate Body Regions-Facial (1970- )

BIOSYSTEMATIC CODES:

- 86215 Hominidae

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA):

- Animals
- Chordates
- Vertebrates
- Mammals
- Primates
- Humans

21/9/5 (Item 5 from file: 5)

DIALOG(R) File 5:Biosis Previews(R)

(c) 2003 BIOSIS. All rts. reserv.

03299623 BIOSIS NO.: 000072027727

**PHONO SURGERY COMBINED APPROACH PALATO PHARYNGO PLASTY**

AUTHOR: GHOSH P

AUTHOR ADDRESS: E-54, ANSARINAGAR, NEW DELHI 110016, INDIA.

JOURNAL: J LARYNGOL OTOL 94 (10). 1980 (RECD. 1981). 1165-1178. 1980

FULL JOURNAL NAME: Journal of Laryngology and Otology

CODEN: JLOTA

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: A new surgical approach (CAP, combined approach palatopharyngoplasty) is described for the correction of speech defects in palatopharyngeal incompetence. In palatopharyngeal incompetence the spatial relationships between the various components of the palatopharyngeal mechanism are disturbed. This combined approach brings about near-normal relationships (intrapalatal and palatopharyngeal), as well as providing a competent palatopharyngeal sphincter, thus offering a remarkable improvement in speech. The operation comprises a 2-stage procedure. The 1st stage includes: **submucosal transplantation** of the levator palati muscles posteriorly to the region of the uvula, and **crossed palatopharyngoplasty**; isolation of the palatopharyngeus muscles (posterior pillars) with their bases superiorly placed at their junctions with the soft **palate**, and **transplantation** of the lower free ends into the transverse retropharyngeal musculo-fascial pockets on the opposite side, the flaps thus crossing each other in the midline. The 2nd stage includes: check-valve palatopharyngoplasty; and elevation of a superiorly based posterior pharyngeal flap with anastomosis to the soft **palate**. The dynamics which are responsible for the improvement in speech are:

elevation of the **palate** to approximately the level of the atlas; and statico-dynamic constriction of the pharyngeal phonetic passage at the following levels: at the newly placed levator eminence, at the newly constructed dynamic sphincter situated between the above-mentioned crossing and the free margin of the soft **palate**, and at the junction of the check-valve flap with the posterior pharyngeal wall; and increase in the effective length of the soft **palate**. The phonetic stream is prevented from entering the **nasal** chambers during the utterance of non-**nasal** pressure sounds by the newly constructed 3-tier protective mechanism. This is identical with, but a reverse representation of, the normal 3-tier protective mechanism of the **larynx**, which prevents food from entering the tracheo-bronchial tree during deglutition. The operation was performed in 8 cases and the results are satisfactory, in so far as improvement in the quality of speech is better than that observed following other operations.

DESCRIPTORS: HUMAN PALATO PHARYNGEAL INCOMPETENCE MUSCLE SOFT **PALATE**  
**NASAL** CHAMBER TRACHEO BRONCHIAL TREE

## CONCEPT CODES:

- 11105 Anatomy and Histology, General and Comparative-Surgery
- 20001 Sense Organs, Associated Structures and Functions-General; Methods
- 20006 Sense Organs, Associated Structures and Functions-Pathology
- 20008 Sense Organs, Associated Structures and Functions-Deafness, Speech and Hearing
- 12512 Pathology, General and Miscellaneous-Therapy (1971- )
- 14001 Digestive System-General; Methods
- 16001 Respiratory System-General; Methods
- 17501 Muscle-General; Methods
- 17506 Muscle-Pathology
- 19001 Dental and Oral Biology-General; Methods
- 19006 Dental and Oral Biology-Pathology

## BIOSYSTEMATIC CODES:

- 86215 Hominidae

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA):

- Animals
- Chordates
- Vertebrates
- Mammals
- Primates
- Humans

21/9/6 (Item 1 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

04590784 EMBASE No: 1991084827

Nose and paranasal augmentation: Autogenous, fascia, and cartilage

Guerrerosantos J.

Division of Plastic, Reconstructive, and Maxillofacial Surgery, Medical College, University of Guadalajara, Garibaldi 1793, Guadalajara Mexico Clinics in Plastic Surgery ( CLIN. PLAST. SURG. ) (United States) 1991, 18/1 (65-86)

CODEN: CPSUD ISSN: 0094-1298

DOCUMENT TYPE: Journal; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

The up-to-date plastic surgeon should consider using augmentation rhinoplasty with relative frequency. In selected cases, for improving the

Serial 09/857307

August 13, 2003

face integrally, it is desirable to augment the paranasal area. In the author's hands, **grafts** of cartilage and fascia are the preferred tissues, based on the experience of many years. Fascia can be used alone or combined, and in the last few years we have used it alone quite often. A temporoparietal fascia **graft** has great versatility in the correction of a number of **nasal** deformities. A depressed **nasal** dorsum can be augmented by utilizing fascia **grafts**. A depressed **nasal** radix can be corrected successfully by utilizing fascia **grafts**. **Submucosal** placement of strips of fascia has proved to be an effective method of reconstructing the roof of the middle cartilaginous vault. For augmenting the **nasal** dorsum when it is a case of primary rhinoplasty, the author prefers the use of fascia alone, but if the patient is having a secondary rhinoplasty, then the **graft** of fascia and cartilage combined is preferred.

## MEDICAL DESCRIPTORS:

\*autograft; \* **nose** cartilage; \* **nose** reconstruction  
adolescent; adult; clinical article; fascia; female; human; male; osteotomy  
; review; surgery

## SECTION HEADINGS:

011 Otorhinolaryngology  
034 Plastic Surgery

25/6/1 (Item 1 from file: 5)  
11765620 BIOSIS NO.: 199900011729

Larynx -preserving resection of the cervical esophagus for cervical esophageal carcinoma limited to the submucosal layer.

1998

25/6/5 (Item 5 from file: 5)  
05546072 BIOSIS NO.: 000083019212

THE VALUE OF INJECTABLE COLLAGEN IN VOCAL AND GLOTTIC REHABILITATION  
1986

25/6/9 (Item 4 from file: 73)  
04869178 EMBASE No: 1992009393  
Subtotal submucosal cricoid resection: An experimental study  
1991

25/6/10 (Item 5 from file: 73)  
03228863 EMBASE No: 1986071440  
Management of chronic aspiration by subtotal and submucosal cricoid resection  
1985

25/6/12 (Item 7 from file: 73)  
01901247 EMBASE No: 1981144411  
The biocompatibility of aluminium oxide implants in middle ear surgery  
1980

25/9/3 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.  
10586040 BIOSIS NO.: 199699207185  
Variants of plastic reconstruction of the external nose .  
AUTHOR: Tsukerberg L I; Svistushkin V M  
AUTHOR ADDRESS: Dep. Otorhinolaryngol., I.M. Sechenov Mosc. Med. Acad.,  
Moscow\*\*Russia

Serial 09/857307

August 13, 2003

JOURNAL: Vestnik Otorinolaringologii 0 (3):p45-47 1996

ISSN: 0042-4668

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: Russian; Non-English

SUMMARY LANGUAGE: English

ABSTRACT: The operative procedure performed for marked deformity of the external nose includes the following stages: re-establishment of nasal breathing (submucosal resection of the nasal septum), plastic repair of the external nose (correction of scoliosis by means of mobilization of the nasal bones, repair of the saddle nose using cartilage transplants). Rethy method allowed optimization of the operative procedure. A simple and reliable scheme of external nose immobilization is outlined.

## DESCRIPTORS:

MAJOR CONCEPTS: Pathology; Physiology; Respiratory System (Respiration);

Sense Organs (Sensory Reception)

BIOSYSTEMATIC NAMES: Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGANISMS: human (Hominidae)

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA): animals; chordates; humans; mammals; primates; vertebrates

MISCELLANEOUS TERMS: CASE STUDY; MARKED DEFORMITY; **NASAL BREATHING**; PROTOCOL; RETHY METHOD; **SURGERY** OPTIMIZATION

## CONCEPT CODES:

11107 Anatomy and Histology, General and Comparative-Regeneration and Transplantation (1971- )

12512 Pathology, General and Miscellaneous-Therapy (1971- )

16001 Respiratory System-General; Methods

20001 Sense Organs, Associated Structures and Functions-General; Methods

## BIOSYSTEMATIC CODES:

86215 Hominidae

25/9/6 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

06214829 EMBASE No: 1995248661

**Use of cultured mucosal grafts to cover defects caused by vestibuloplasty: An in vivo study**

Raghoobar G.M.; Tomson A.M.; Scholma J.; Blaauw E.H.; Witjes M.J.H.; Vissink A.; Lauer G.

Dept. of Oral/Maxillofacial Surgery, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen Netherlands

Journal of Oral and Maxillofacial Surgery ( J. ORAL MAXILLOFAC. SURG. ) ( United States ) 1995, 53/8 (872-879)

CODEN: JOMSD ISSN: 0278-2391

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Purpose: In oral and maxillofacial surgery **palatal** mucosal **grafts** are routinely used to cover mucosal defects caused by vestibuloplasty. However, the quantity of **palatal** mucosa is a limiting factor in more extensive operations. This study investigated whether autologous cultured sheets of mucosa can serve as a dressing for these wounds. Materials and Methods: Punch biopsies (diameter, 4 mm) were taken from the hard **palate** of eight patients (five men, three women; mean age 43 years). Epithelial cells were enzymatically dissociated from these tissue specimens and grown in vitro in

the presence of a fibroblast feeder layer. Within 3 weeks, a **transplantable** epithelial sheet of about 20 cmsup 2 was obtained. The sheet was detached from the culture flask by enzyme treatment and fixed to a carrier of Vaseline (Cheeseborough Ponds Inc, Greenwich, CT) gauze. Using a split-mouth technique, the sheet was placed on half of a mucosal defect created by vestibuloplasty, while the other half of the defect was covered by a conventional split-thickness **palatal graft**. Both the cultured and conventional **graft** were held in place by the patient's relined denture fixed with perimandibular sutures. One week postsurgery, the denture and Vaseline gauze were removed. Three months after vestibuloplasty, biopsy specimens of each **grafted** site were taken and processed for light and transmission electron microscopy (LM, TEM). Results: Three months postsurgery, the **grafted** mucosa of both sites bore close resemblance to **palatal** mucosa. Both the cultured and split-thickness **grafts** were vascularized, did not evoke a **homograft** reaction, and showed a smooth **graft** /lip mucosal junction and minimal wound contraction. LM and TEM revealed that both types of **grafts** formed a fully differentiated keratinizing mucosa with a well-developed **basement membrane** and rete ridges, comparable with the histology and ultrastructure of **palatal** mucosa in situ. Conclusion: It was concluded from this study that cultured mucosa can serve as a proper dressing for mucosal defects after vestibuloplasty.

## MEDICAL DESCRIPTORS:

\*mouth malformation-- **surgery** -- su ; \*oral **surgery**  
adult; article; clinical article; female; hard **palate** ; human; human tissue; male; mouth mucosa; postoperative complication; **surgical** technique; tissue culture

## SECTION HEADINGS:

009 Surgery  
011 Otorhinolaryngology

25/9/7 (Item 2 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

05660489 EMBASE No: 1994076717

**Monobloc correction of external nasal deviations**

Barone C.M.; Argamaso R.V.; Sterman H.; Pelham F.; Strauch B.

Division of Plastic Surgery, University of Missouri, One Hospital Drive, Columbia, MO 65212 United States

Journal of Craniofacial Surgery ( J. CRANIOFAC. SURG. ) (United States)

1994, 5/1 (61-66)

CODEN: JSURE ISSN: 1049-2275

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

Nine patients (7 men, 2 women) with external **nasal** deviation underwent corrective procedures using a monobloc **nasal** osteotomy technique. The deformities ranged from mild to severe. Eight patients had post-traumatic deviations, whereas 1 had a unilateral cleft **nasal** deformity. For this monobloc technique, osteotomies were performed at unequal levels to correct the height difference, no periosteal undermining was performed, and septal dissection was undertaken only after monobloc repositioning. There was no need for **grafts** or microplate fixation. Minimum follow-up was 8 months. All patients had improvement in their external deviation, 1 patient was mildly undercorrected, and only 1 patient (cleft **nasal** ) required a radical **submucosal** resection.

## MEDICAL DESCRIPTORS:

\* **nose** malformation--congenital disorder--cn; \* **nose** malformation--surgery -- su ; \* **nose malformation** --etiology--et; \* **surgical** approach adolescent; adult; article; clinical article; female; follow up; human; injury--etiology--et; male; osteotomy; priority journal

SECTION HEADINGS:

009 Surgery  
011 Otorhinolaryngology

25/9/11 (Item 6 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

02741670 EMBASE No: 1984060629

**Spreader graft: A method of reconstructing the roof of the middle nasal vault following rhinoplasty**

Sheen J.H.

9201 Sunset Boulevard, Suite 814, Los Angeles, CA 90069 United States  
Plastic and Reconstructive Surgery ( PLAST. RECONSTR. SURG. ) (United  
States) 1984, 73/2 (230-239)

CODEN: PRSUA

DOCUMENT TYPE: Journal

LANGUAGE: ENGLISH

**Submucosal** placement of strips of cartilage along the anterior border of the septum - the spreader **graft** - has proved to be an effective method for reconstructing the roof of the middle vault. It is recommended in all primary rhinoplasty patients in whom resection of the roof of the upper cartilaginous vault is a necessary part of the **surgical** plan.

MEDICAL DESCRIPTORS:

\***cartilage graft**

**nose** reconstruction; methodology; human; therapy; case report; cartilage  
MEDICAL TERMS (UNCONTROLLED): **nose** bridge

SECTION HEADINGS:

034 Plastic Surgery

011 Otorhinolaryngology

25/9/13 (Item 8 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

00658795 EMBASE No: 1977004121

**Radical surgery of the larynx and laryngopharynx**

CANCER OF THE HEAD AND NECK. ICS NO. 365

Lore Jr. J.M.

Dept. Otolaryngol., State Univ. New York, Buffalo, N.Y. United States  
1975, (140-152)

CODEN: BOOKA

DOCUMENT TYPE: Book

LANGUAGE: ENGLISH

It is beyond the scope of this presentation to detail all the various aspects of the indication for total **laryngectomy** and radical neck dissection, as well as the various applications of radiotherapy and chemotherapy in the treatment of carcinoma of the **larynx** and laryngopharynx. In general, removal of the entire **larynx** is indicated with **vocal cord** fixation, those lesions classified as T3 and T4, and all subglottic cancers. Some T2 cancers may require total **laryngectomy**. It is recommended that subglottic lesions, if treated surgically, have a homolateral thyroid lobectomy and isthmusectomy, paratracheal and tracheoesophageal node dissection. The basic technique of total

**laryngectomy** recommended is that which includes the major portion of the juxtaposed strap muscles. Careful evaluation of the extent of the lesion, not only by prior endoscopic examination but also careful evaluation at the time of surgery, basically involves an approach for visualization of the **larynx**, from the side opposite the gross extent of the disease. In other words, if the lesion involves the left side of the **larynx**, a contralateral approach via the right pyriform sinus or hypopharynx is utilized. By the same token, an initial transhyoid or suprathyoid exposure is contraindicated in those lesions which involve the lingual side of the epiglottis for fear of cutting into the tumor. Depending on this evaluation of the extent of the disease, a portion of the hypopharynx may require resection. When this is the case, margins of the hypopharynx should be at least 2 cm because of the **submucosal** spread of squamous cell carcinoma once it reaches the pharynx. Liberal use of frozen section to ascertain free margins is recommended. The following aspects are dealt with: total **laryngectomy** and radical neck dissection: total laryngopharyngectomy; reconstruction, and tongue flap and dermal **graft** for reconstruction of the entire hypopharynx, portion of oropharynx and cervical esophagus associated with laryngopharyngectomy. Several diagrams are included.

## MEDICAL DESCRIPTORS:

\* **laryngectomy** ; \* **larynx cancer** ; \*neck dissection; \* **ear nose throat surgery**

therapy

## SECTION HEADINGS:

011 Otorhinolaryngology

016 Cancer

009 Surgery

25/9/14 (Item 9 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

00657904 EMBASE No: 1977003230

**Sequential electron microscopic healing study of grafted palatal mucosa**  
Weinstein R.A.; Rubinstein A.S.; Choukas N.C.

Loyola Univ. Sch. Dent., Maywood, Ill. 60153 United States

Journal of Dental Research ( J. DENT. RES. ) 1976, 55/1 (16-21)

CODEN: JDREA

DOCUMENT TYPE: Journal

LANGUAGE: ENGLISH

Human **palatal** mucosa may be glycerolized, frozen, thawed and autogenically **transplanted** with success after a storage period. Although tissue damage is observed, both at the light and electron microscopic level, this is not clinically significant. This damage is attributed to the glycerolization, freezing, and thawing process. As evidenced primarily by this ultrastructural study, regeneration of **grafted** epithelium is effected via the basal cell layer. The formation of intracytoplasmic vesicular structures and alterations in both the **basal lamina** and intercellular substances may play a significant role in the regenerative process. The electron microscope elucidated changes in regenerating cells that have not been previously observed by light microscopy. It appeared that the regeneration was almost complete 30 days posttransplantation.

## MEDICAL DESCRIPTORS:

\*mouth mucosa; \*oral **surgery** ; \*transplantation; \*wound healing methodology; therapy; electron microscopy; major clinical study; diagnosis

MEDICAL TERMS (UNCONTROLLED): **palate mucosa**

## SECTION HEADINGS:

011 Otorhinolaryngology  
005 General Pathology and Pathological Anatomy  
001 Anatomy, Anthropology, Embryology and Histology

25/9/15 (Item 1 from file: 144)

DIALOG(R)File 144:Pascal  
(c) 2003 INIST/CNRS. All rts. reserv.  
10479622 PASCAL No.: 92-0683116  
**Two-stage repair of extensive subglottic tracheal stenosis**  
SOMERS T; MARQUET J; OFFECIERS E  
Medisch inst. Sint-Augustinus, univ. dep. oto-rhinolaryngology - head  
neck surgery, Wilrijk 2610, Belgium  
Journal: European archives of oto-rhino-laryngology, 1990, 248 (2) 82-86  
Availability: INIST-8242; 354000018209770050  
No. of Refs.: 34 ref.  
Document Type: P (Serial) ; A (Analytic)  
Country of Publication: Federal Republic of Germany  
Language: English  
The authors describe an open technique that has been used over the past  
25 years to reconstruct the subglottic tracheal region in two stages after  
extensive laryngotracheal stenosis. After **submucosal** resection of fibrous  
tissue and reconstruction of the subglottic and tracheal skeleton by means  
of two autologous osseous **grafts**, a large laryngotracheostomy is created  
during the initial stage. Some weeks later, in the second stage, the  
anterior wall is closed, using two cervical hinge-door flaps. Ten patients  
have undergone this procedure, with a minimum follow-up of 3 years.  
English Descriptors: Stenosis; Laryngotracheal; Technique; **Surgery** ;  
**Larynx disease** ; Diseases of the trachea; Human; Treatment; ENT disease;  
Respiratory disease  
Classification Codes: 002B25C01

25/9/16 (Item 1 from file: 94)

DIALOG(R)File 94:JICST-EPlus  
(c)2003 Japan Science and Tech Corp(JST). All rts. reserv.  
02124692 JICST ACCESSION NUMBER: 95A0363477 FILE SEGMENT: PreJICST-E  
**A New technique for reconstruction of the alveolar ridge with the palatal  
flap.**

OSHIMA AKIHISA (1)  
(1) Runadentarukurinikku

Aichi Gakuin Daigaku Shigakkaishi (Aichi-Gakuin Journal of Dental Science),  
1995, VOL.33,NO.1, PAGE.283-290

JOURNAL NUMBER: Y0095AAC ISSN NO: 0044-6912

LANGUAGE: Japanese COUNTRY OF PUBLICATION: Japan

DOCUMENT TYPE: Journal

MEDIA TYPE: Printed Publication

ABSTRACT: Many **surgical** techniques have been introduced for  
reconstruction of the alveolar ridge. We devised a new technique using  
a **palatal** periosteal flap as a free **graft** to overcome the  
disadvantages of some procedures. The **surgical** technique: The  
**palatal** mucosa is incised to a certain depth and on initial **palatal**  
flap is made leaving a certain width of the gingiva to a certain depth  
as a pedicle flap. Then the underlying layer of the periosteal flap is  
removed as a free flap. The primary pedicle flap is then returned to  
its original position and sutured to obtain a primary closure.  
Consequently, neither the bone nor the raw surface of the donor site  
are left exposed. In the recipient site, the vestibular mucosa is

incised to a certain depth and extended by pushing downward. Then the bone surface is exposed by 2\*1cm to prevent a relapse by removing the **submucosal** connective tissue as in the periosteal fenestration technique. The prepared **palatal** periosteal flap is **grafted** over the exposed bone surface. We have applied this technique in 12 cases to reconstruct the alveolar ridge. This technique gives the patient minimal discomfort, provides early healing of both wounds, and leaves no esthetic disturbance. (author abst.)

26/6/7 (Item 2 from file: 73)

03643116 EMBASE No: 1988092552

Hydron gel implants in vocal cords  
1988

26/6/8 (Item 3 from file: 73)

03065349 EMBASE No: 1986256365

The value of injectable collage in vocal and glottic rehabilitation  
1986

26/3,K/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)  
(c) 2003 BIOSIS. All rts. reserv.

07265898 BIOSIS NO.: 000090045774

#### EPIGLOTTIC AUGMENTATION IN THE HORSE

AUTHOR: TULLENERS E; MANN P; RAKER C W

AUTHOR ADDRESS: DVM, NEW BOLTON CENT., 382 WEST STREET RD., KENNETT SQUARE, PA. 19348.

JOURNAL: VET SURG 19 (3). 1990. 181-190. 1990

FULL JOURNAL NAME: Veterinary Surgery

CODEN: VESUD

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: Epiglottic augmentation with injectable bovine collagen or an autogenous oralogenous **auricular** cartilage **graft** was performed in 12 horses with endoscopically and radiographically normal epiglottises. The **grafting** procedures were easy to perform and did not cause apparent discomfort. Cartilage **graft** extrusion or resorption may have occurred, but was not seen by endoscopy and lateral **laryngeal** radiography. Only collagen **implants** remained evident endoscopically, as smooth round **submucosal** bulges ventral to the epiglottic cartilage. Two horses with collagen **implants**, and all horses with cartilage **autografts** and **allografts**, were euthanatized at week 16. One horse with a collagen **implant** was euthanatized at week 4 and one at week 6. The epiglottis appeared thickened in three horses with collagen **implants**, two horses with autogenous **grafts**, and three horses with allogenous **grafts**. Pharyngeal lymphoid tissue was hyperplastic in two horses with **autografts** and three horses with **allografts**, but not in horses with collagen **implants**. Collagen **grafts** persisted as one or two by smooth bulges 8 mm in diameter. Collagen incited a...  
...that was surrounded by a fibrous connective tissue capsule. Epiglottises of the horses with collagen **implants** were significantly thicker 20 mm from the tip than those of normal horses and horses with **allografts**. Cartilage **graft** incorporation was not evident grossly and was seen on microscopic examination in only one **autograft**. Thickening was caused by **submucosal** fibrosis.

DESCRIPTORS: ENDOSCOPY LARYNGEAL RADIOLOGY COLLAGEN GRAFT

## 26/3,K/6 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.  
05800889 EMBASE No: 1994217350**Tissue-engineered morphogenesis of cartilage and bone by means of cell transplantation using synthetic biodegradable polymer matrices**

Vacanti C.A.; Upton J.

Department of Anesthesia-White 5, Massachusetts General Hospital, Boston,  
MA 02114 United StatesClinics in Plastic Surgery ( CLIN. PLAST. SURG. ) (United States) 1994,  
21/3 (445-462)

CODEN: CPSUD ISSN: 0094-1298

DOCUMENT TYPE: Journal; Review

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

...cells onto synthetic biocompatible, biodegradable polymers of different chemical compositions and physical configurations, and then transplanting these polymers into animals. The synthetic scaffolds act as a basement membrane providing for structural cues and enabling nutrition by diffusion until grafting occurs. The development of this field since its inception as well as several potential applications...

## MEDICAL DESCRIPTORS:

articular cartilage; biodegradation; bioengineering; bone remodeling; ear reconstruction; extracellular matrix; morphogenesis; nonhuman; nude mouse; rabbit; review

## 26/3,K/9 (Item 4 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.  
02089842 EMBASE No: 1982192938**Repair of a subglottic stenosis by submucosal resection**

Steensen S.H.; Petersen J.W.

ENT Dept. Munic. Hosp., Copenhagen Denmark

Journal of Laryngology and Otology ( J. LARYNGOL. OTOL. ) (United Kingdom ) 1982, 96/5 (469-471)

CODEN: JLOTA

DOCUMENT TYPE: Journal

LANGUAGE: ENGLISH

A subglottic, intralaryngeal stenosis in a 5 year old boy was successfully removed by microsurgical submucosal resection. The method reported provides adequate subglottic augmentation and interferes with the laryngeal cartilage only minimally. The use of small split-thickness skin grafts for lining material is advocated, as they take immediately and reduce the time for stenting. At follow-up, no recurrent stenosis has developed and the site of the skin grafts has been lined with ciliated mucosa. Post-operative hospitalization was considered to be acceptably short.

## MEDICAL DESCRIPTORS:

\*intubation; \* larynx stenosis

upper respiratory tract obstruction; case report; larynx ; respiratory system

## 26/3,K/11 (Item 6 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.  
00649155 EMBASE No: 1976204828

**Histological examinations of ingrowing of free oral mucous grafts in the larynx**

HISTOLOGISCHE UNTERSUCHUNGEN UBER DIE EINHEILUNG FREIER MUND SCHLEIMHAUT TRANSPLANTATE IM GLOTTISBEREICH

Neumann O.G.

Germany

Archives of Oto-Rhino-Laryngology ( ARCH. OTO-RHINO-LARYNGOL. ) 1975, 210/2 (244-246)

CODEN: AORLC

DOCUMENT TYPE: Journal

LANGUAGE: GERMAN

In more than 50 cases of **grafting** free oral mucous flaps for glottic reconstruction no clinical results of healing were found. From different patients biopsies of oral mucous **grafted vocal cords** had been taken after 3 wk, 3, 9, 15, 16 mth. In several microphotographs it is shown that the mucous of the **grafts** as good as the adjoining mucous of the **larynx** has not changed the original structure. In the covered muscle and the **submucosal** elastic elements there cannot be found any important sign of degeneration or cicatrization.

MEDICAL DESCRIPTORS:

\* **larynx** ; \***papillomatosis**

**26/3,K/15 (Item 10 from file: 73)**

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

00199839 EMBASE No: 1974189982

**A simple technique for plastic closure of large septal perforations**

EIN EINFACHES VERFAHREN ZUM PLASTISCHEN VERSCHLUSS GROSSER

SEPTUMPERFORATIONEN

Koburg E.

Germany

ARCH.KLIN.EXP.OHR.NAS.KEHLK.HEILK. 1973, 205/2 (289-291)

CODEN: AKONA

DOCUMENT TYPE: Journal

LANGUAGE: GERMAN

...a simple method for the repair of septal perforation which consists of: formation of a **submucosal** pocket proximal to the perforation, introduction of a skin **graft** folded on itself, with raw surfaces on both sides into the pocket, and incision comprising...

MEDICAL DESCRIPTORS:

\* **nose** reconstruction; \* **nose** septum; \* **nose** septum perforation

**26/3,K/16 (Item 11 from file: 73)**

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

00167646 EMBASE No: 1974157770

**Complications and other sequelae of functional and corrective nasal surgery**

COMPLICANZE ED ESITI NELLA CHIRURGIA FUNZIONALE E CORRETTIVA DEL NASO  
Fruttero F.

Clin. ORL, Univ. Torino Italy

Minerva Otorinolaringologica ( MINERVA OTORINOLARINGOL. ) 1973, 23/3 (138-143)

CODEN: MIOTA

DOCUMENT TYPE: Journal

LANGUAGE: ITALIAN

Various aspects of the physiopathology of the **nasal** passages are described and complications arising intra and post operatively in functional and plastic management of the **nose** are explained. These include: haemorrhage, hard oedema, hyperostosis, **graft** necrosis, infection, decubitus lesions, frontal sinus lesions, lesions of the lamina cribrosa and lacrimal, perforations, and cosmetically unsatisfactory results following **submucosal** resection of the septum. Attention is also given to anosmia and respiratory insufficiency as possible, though rare, complications arising after operations designed to improve the cosmetic appearance of the **nasal** bridge.

MEDICAL DESCRIPTORS:

\*anosmia; \*bleeding; \*edema; \* **nose** reconstruction

MEDICAL TERMS (UNCONTROLLED): saddle **nose**

File 98:General Sci Abs/Full-Text 1984-2003/Jun  
 File 9:Business & Industry(R) Jul/1994-2003/Aug 12  
 File 16:Gale Group PROMT(R) 1990-2003/Aug 13  
 File 160:Gale Group PROMT(R) 1972-1989  
 File 148:Gale Group Trade & Industry DB 1976-2003/Aug 13  
 File 441:ESPICOM Pharm&Med DEVICE NEWS 2003/Aug W2  
 File 621:Gale Group New Prod.Annou.(R) 1985-2003/Aug 13  
 File 149:TGG Health&Wellness DB(SM) 1976-2003/Jul W4  
 File 636:Gale Group Newsletter DB(TM) 1987-2003/Aug 13  
 File 20:Dialog Global Reporter 1997-2003/Aug 13  
 File 444:New England Journal of Med. 1985-2003/Aug W3  
 Set Items Description  
 S1 5460 SUBMUCOSA? ? OR (BASEMENT OR HYALINE) () MEMBRANE? ? OR (BAS-  
     AL OR BASEMENT) () LAMINA? ?  
 S2 34448 VOCAL() (CORD? ? OR FOLD? ?) OR LARYNX OR LARYNGE? OR PALAT-  
     E? ? OR PALATAL  
 S3 389328 NASAL OR NOSE OR AURICULA? ? OR EAR OR EARS  
 S4 548 (HEAD OR NECK) (2N) TISSUE  
 S5 110281 GRAFT? OR HOMOGRAFT? OR HETEROGRAFT? OR ALLOGRAFT? OR AUTO-  
     GRAFT?  
 S6 296398 IMPLANT? OR TRANSPLANT?  
 S7 56 S1(3N) S5:S6  
 S8 761023 SURGERY OR SURGICAL  
 S9 1 S2:S4(S)S7  
 S10 258 S1(S)S5:S6 NOT S7  
 S11 9 S2:S4(S)S10  
 S12 9 S11 NOT S9  
 S13 7 RD (unique items)  
 S14 3 S13/1999:2003  
 S15 4 S13 NOT S14

9/7/1 (Item 1 from file: 636)

DIALOG(R) File 636:Gale Group Newsletter DB(TM)

(c) 2003 The Gale Group. All rts. reserv.

01316011 Supplier Number: 41522229 (THIS IS THE FULLTEXT)

Behaviour of alloplastic tympanic membranes in staphylococcus aureus-induced middle ear infection. II. Morphological study of epithelial reactions.

Biomedical Materials, pn/A

Sept, 1990

TEXT:

Epithelial reactions to Silastic, Estane polyether urethane, polypropylene oxide, and a poly(ethylene oxide hydantoin) and poly(tetramethylene terephthalate) segmented polyether polyester copolymer were investigated after implantation in tympanic membranes and submucosa of non-infected and *Staphylococcus aureus*-infected rat middle ears. After initial swelling caused by the surgical trauma, neither the proliferative activity nor the composition of the epithelium covering submucosal implants was found to be affected by the presence of any of the biomaterials. (Bakker D. et al, J.Biomed. Mat. Res., 24, 7, 1990, p. 809-28; University Hospital, Leiden, The Netherlands.)

COPYRIGHT 1990 Elsevier Science Publishers B.V.

THIS IS THE FULL TEXT: COPYRIGHT 1990 International Newsletters

Subscription: \$219 per year as of 1/92. Published monthly. Contact Elsevier Advanced Technology Publications, Crown House, Linton Road, Barking, Essex, IG11 8JU, U.K. Phone 01-594-7272.

COPYRIGHT 1999 Gale Group

**15/3,AB,K/1 (Item 1 from file: 16)**

DIALOG(R)File 16:Gale Group PROMT(R)  
(c) 2003 The Gale Group. All rts. reserv.

04599551 Supplier Number: 46763988

**Autologous tissue can improve graft safety**

Ophthalmology Times, p12

Oct 1, 1996

Language: English Record Type: Fulltext

Document Type: Magazine/Journal; Trade

Word Count: 872

... when harvesting hard palate mucosa grafts. (Figures 1A and 1B)

The mucosa of the hard **palate** consists of a stratified squamous epithelium, with variable degrees of keratinization, resting on a collagenous lamina propria (Figure 2). The hard **palate** sub-mucosa consists of a richly innervated and vascularized loose, fatty connective tissue. Beneath the **submucosa** is the periosteum of the hard **palate**. Dissection of a hard **palate** **graft** should proceed in the **submucosal** plane, leaving the periosteum undisturbed.

**Surgical technique**

The procedure can be performed under general or...

...and then balloon the mucosa from the underlying periosteum. This turns the normally pink hard **palate** mucosa white. A scalpel blade is used to incise the mucosal area demarcated (Figure 3), followed by dissection in a **submucosal** plane to remove the **graft**. Care must be taken to avoid deep dissection to the periosteum as this can delay...

**15/3,AB,K/2 (Item 1 from file: 149)**

DIALOG(R)File 149:TGG Health&Wellness DB(SM)

(c) 2003 The Gale Group. All rts. reserv.

01619731 SUPPLIER NUMBER: 18306605 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**Cystic fibrosis in adults: from researcher to practitioner.**

Marelich, Gregory P.; Cross, Carroll E.

The Western Journal of Medicine, v164, n4, p321(14)

April, 1996

PUBLICATION FORMAT: Magazine/Journal ISSN: 0093-0415 LANGUAGE: English  
RECORD TYPE: Fulltext; Abstract TARGET AUDIENCE: Professional

WORD COUNT: 13175 LINE COUNT: 01133

AUTHOR ABSTRACT: The Cystic Fibrosis Foundation currently tracks about 20,000 Americans with cystic fibrosis, an autosomal recessive genetic disease that leads to multisystem complications. With the institution of better therapeutic regimens over the past 2 decades, more patients with this disease are surviving to adulthood. Within the past decade, both clinical and basic science research in the field of cystic fibrosis has progressed at a rapid rate. The intent of this review is to introduce readers to the molecular, cellular, and systemic disorders of this disease. We discuss treatment strategies involving antibiotics, nutrition, immune-response mediators, chest physiotherapy, and sputum-active agents with respect to the airway dysfunction of cystic fibrosis. Other common complications, recent developments, transplantation, and gene therapy are also reviewed.

...**Submucosal** glands are the predominant site of CFTR expression in the human bronchus...1992...

...Bavaria JE, Kaiser LR, Wilson JM, Albelda SM: Adenovirus-mediated gene transfer to human bronchial **submucosal** glands using xenografts. Am J

ASRC Searcher: Jeanne Horrigan

Serial 09/857307

August 13, 2003

37

Physiol 1995; 268:L657-L665 [141.] Yei S, Mittereder N...

File 350:Derwent WPIX 1963-2003/UD, UM &UP=200351  
 File 347:JAPIO Oct 1976-2003/Apr (Updated 030804)  
 File 371:French Patents 1961-2002/BOPI 200209

Set	Items	Description
S1	558	SUBMUCOSA? ? OR (BASEMENT OR HYALINE) () MEMBRANE? ? OR (BAS- AL OR BASEMENT) () LAMINA? ?
S2	4016	VOCAL() (CORD? ? OR FOLD? ?) OR LARYNX OR LARYNGE? OR PALAT- E? ? OR PALATAL
S3	58408	NASAL OR NOSE OR AURICULA? ? OR EAR OR EARS
S4	183	(HEAD OR NECK) (2N) TISSUE
S5	56857	GRAFT? OR HOMOGRAFT? OR HETEROGRAFT? OR ALLOGRAFT? OR AUTO- GRAFT?
S6	154785	IMPLANT? OR TRANSPLANT?
S7	10521	IC=A61L-027
S8	26812	IC=A61F-002
S9	4173	S8 AND S7
S10	93	S1(S) S5:S6
S11	7	S2:S3 AND S10
S12	1	S4 AND S10
S13	8	S11:S12
S14	2	<b>S9 AND S13 [duplicates]</b>
S15	6	<b>S13 NOT S14</b>
S16	12	S1 AND S2:S4 AND S5:S6
S17	4	<b>S16 NOT S13</b>

15/34/1 (Item 1 from file: 350)

DIALOG(R) File 350:Derwent WPIX  
 (c) 2003 Thomson Derwent. All rts. reserv.

015168712

WPI Acc No: 2003-229240/200322

Preparation of submucosal xenograft for implantation into human for  
 replacing defective human tissue, involves removing portion of submucosa  
 from non-human animal, washing and digesting with glycosidase

Patent Assignee: CROSSCART INC (CROS-N); STONE K R (STON-I)

Inventor: STONE K R

Number of Countries: 089 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 200289711	A1	20021114	WO 2002US12295	A	20020418	200322 B

Priority Applications (No Type Date): US 2001289328 P 20010507

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
WO 200289711	A1	E	23 A61F-002/38	

Designated States (National): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN  
 CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ  
 LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK  
 SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

Designated States (Regional): AT BE CH CY DE DK EA ES FI FR GB GH GM GR  
 IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZM ZW

Abstract (Basic): WO 200289711 A1

NOVELTY - Preparing a **submucosal** xenograft for **implantation** into human, involves removing **submucosal** from non-human animal to provide the xenograft, washing in water and alcohol, subjecting to cellular disruption treatment and digesting with glycoside to remove surface carbohydrate groups from the xenograft. The xenograft is non-immunogenic and has same mechanical properties as native soft

tissue.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) an article, which comprises a substantially non-immunogenic **submucosal** xenograft for **implantation** into human body; and  
(2) a **submucosal** xenograft tissue for **implantation** into human, which comprises a portion of **submucosal** tissue from non-human animal. The portion includes extracellular component(s) and dead cell(s) having no surface- galactosyl groups. The xenograft tissue is non-immunogenic in a primate.

USE - For replacement and repair of defective human tissue. The xenograft is useful in urinary incontinence, large or chronic dermal injuries and has other applications such as an adhesion barrier, as an organ patch, hemostatic plug, in treating cleft **palate**, normal wound care etc.

ADVANTAGE - The xenograft is non-immunogenic and has elasticity, load bearing capacity and mechanical properties as a portion of native soft tissue. The xenograft further has significant structure, and holding strength.

pp; 23 DwgNo 0/0

Technology Focus:

TECHNOLOGY FOCUS - INSTRUMENTATION AND TESTING - Preferred Process: The disruption treatment involves freeze/thaw cycling and exposure to gamma radiation. The xenograft is prepared from peptidoglycan(s) by digesting the xenograft with proteoglycan depleting factor such as chondroitinase ABC, hyaluronidase, chondroitin AC II lyase, keratanase, trypsin and/or fibronectin fragment. The method further involves piercing the xenograft, treating the xenograft with at least one enzyme, anticalcification agents, antithrombotic agents, antibiotics and/or growth factors, sterilizing the xenograft and treating the xenograft with cross-linking agent and polyethylene glycol.

BIOLOGY - Preferred Components: The glycosidase is alpha-galactosidase. The enzyme is officin or trypsin. The sterilizing agent is ethylene oxide or propylene oxide. The cross-linking agent is aldehyde, aromatic diamines, carbodiimides, diisocyanates or glutaraldehyde (0.01-5 % glutaraldehyde). The cross-linking agent is in vapor form. The xenograft tissue is excised from the jejunum of warm blooded vertebrate. The portion is segment of small intestine such as tunical submucosa, muscularis mucosa, and striatum compactum of the tunica mucosa. The portions are delaminated from the tunical muscularis and luminal portion of the tunical mucosa. The portion of the ligament has a second block bone affixed to the second end and the opposite portion to the first end.

Derwent Class: A96; B07; D16; D21; D22; E13; E17; P32

International Patent Class (Main): A61F-002/38

International Patent Class (Additional): A61F-002/28; A61F-002/30

15/34/2 (Item 2 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

015053372

WPI Acc No: 2003-113888/200311

**Membrane useful for promoting healing of mucosa injury, comprising purified collagen material derived from natural collagen-containing tissue**

Patent Assignee: GEISTLICH SOEHNE CHEM IND AG E (GEIS ); BOYNE P J

(BOYN-I); GEISTLICH P (GEIS-I); SCHLOESSER L (SCHL-I)

Inventor: BOYNE P J; GEISTLICH P; SCHOESSER L; SCHLOESSER L

Number of Countries: 032 Number of Patents: 007

## Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
EP 1252903	A1	20021030	EP 2002252970	A	20020426	200311	B
AU 200235618	A	20021031	AU 200235618	A	20020424	200311	
CA 2383636	A1	20021027	CA 2383636	A	20020426	200311	
US 20020160036	A1	20021031	US 2001286531	P	20010427	200311	
			US 2002128525	A	20020424		
JP 2003010313	A	20030114	JP 2002125350	A	20020426	200316	
CN 1383897	A	20021211	CN 2002118498	A	20020427	200324	
CZ 200201479	A3	20030416	CZ 20021479	A	20020426	200336	

Priority Applications (No Type Date): US 2001286531 P 20010427; US 2002128525 A 20020424

## Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
EP 1252903	A1	E	9 A61L-027/24	
			Designated States (Regional):	AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR
AU 200235618	A			A61L-027/60
CA 2383636	A1	E		A61K-038/39
US 20020160036	A1			A61K-038/39 Provisional application US 2001286531
JP 2003010313	A	20		A61L-031/00
CN 1383897	A			A61L-015/32
CZ 200201479	A3			A61L-027/24

## Abstract (Basic): EP 1252903 A1

NOVELTY - A membrane comprises a purified collagen material derived from natural collagen-containing tissue.

ACTIVITY - Vulnerary.

MECHANISM OF ACTION - None given in the source material.

USE - In the manufacture of membrane for promoting mucosa regeneration by covering an area of mucosa injury with the membrane (claimed) and for promoting healing of mucosa injury (particularly oral mucosa injury).

ADVANTAGE - The membrane biodegrades without an adverse inflammatory response, promotes regeneration of mucosa in any part of the body having damaged mucosal tissue and is technically feasible in surgical manipulation and exhibits tolerance to suturing. The material could also be used as a substitute for free mucosal grafts or split thickness skin grafts in maintaining the vestibular height and in the restoration of attached mucosa in the area of root form implants.

pp; 9 DwgNo 0/3

## Technology Focus:

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Component: The membrane has a thickness of 0.5 - 5 mm and comprises a barrier layer (preferably collagen I and/or collagen III) including an outer smooth barrier face and a fibrous face opposite to the smooth barrier face. The membrane comprises a multi-layer sheet of collagen material adhered to the fibrous face, and the matrix layer comprises collagen I, II, III, IV and/or VII (preferably collagen I or II). The membrane carries at least one mucosa-regenerating growth factor selected from epidermal growth factor (EGF), insulin-like growth factor (IGF-1), fibroblast growth factor (beta-FGF), platelet-derived growth factor (PDGF) and/or transforming growth factor (TGF-beta).

## Extension Abstract:

EXAMPLE - A membrane material was prepared from porcine Type I and

Type III collagen manufactured in two layers, and was placed and secured to the margins of a host mucosal surface with 4-0 monofilament nylon interrupted sutures. Biopsies of the vestibular surgical sites were made at the end of 3 and 6 weeks. At 3 weeks, a biopsy on one side (2 quadrants) of each animal was made to extend the superior native residual host mucosal surface across the surface of membrane material to the opposite inferior graft host margin. The biopsy area was closed with interrupted sutures and allowed to heal. Biopsies of the attached mucosal area were similarly taken: one side at 3 weeks and one side of each animal at 6 weeks for a total of 3 specimens for each period. The sutures in all cases were removed on the 14th post operative day.

There was no clinical evidence of inflammation or infection and no sloughing of the membrane material. The membrane remained in place and the margins indicated gradual re-epithelialization from the host mucosal peripheral surfaces. The biopsies at the end of 3 weeks showed re-epithelialization of the margins with normal rete peg formation. In the 6 week specimens, there was an excellent mucosal surface developed completely across the patched area with evidence of neoangiogenesis submucosally and a normal stratified squamous epithelial formation in evidence with a complete excision and biopsy of the patched area. New attached mucosa could be seen in all of the specimens on the **palatal** surface, on the alveolar ridge crest, and on the buccal aspect of the alveolar ridge. Very small area of residual collagen could be seen beneath the surface epithelium. There was evidence of complete acceptance of the membrane material and excellent re-reformation of attached mucosa.

On the basis of these tests, it was conducted that collagen membrane as a patch was an excellent substitute for autogenous soft tissue **grafts**. There was no evidence of either scarring or prolonged inflammatory response or any evidence of **submucosal** fibrosis, which sometimes occurred.

Derwent Class: B04; D22; P34  
International Patent Class (Main): A61K-038/39; A61L-015/32; A61L-027/24; A61L-027/60; A61L-031/00  
International Patent Class (Additional): A61K-009/70; A61K-038/18; A61K-038/22; A61L-026/00; A61L-027/36

17/34/1 (Item 1 from file: 350)

DIALOG(R)File 350:Derwent WPIX  
(c) 2003 Thomson Derwent. All rts. reserv.  
014583072 \*\*Image available\*\*  
WPI Acc No: 2002-403776/200243

Lateral stiffening snoring treatment method involves linking right and left side locations of soft palate by submucosal linkage of stiffness greater than stiffness of untreated tissue between locations

Patent Assignee: PI MEDICAL INC (PIME-N); RESTORE MEDICAL INC (REST-N)  
Inventor: CONRAD T R; KNUDSON M B; METZGER A K; STEVENS W J; WALTER L A  
Number of Countries: 102 Number of Patents: 003

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 20020035994	A1	20020328	US 99398991	A	19990917	200243 B
			US 99434653	A	19991105	
			US 2000513039	A	20000225	
			US 2000513432	A	20000225	
			US 2000602141	A	20000623	
			US 2000636803	A	20000810	

US 6502574	B2	20030107	US 2001814460	A	20010321
			US 2001992277	A	20011114
			US 99398991	A	19990917 200306
			US 99434653	A	19991105
			US 2000513039	A	20000225
			US 2000513432	A	20000225
			US 2000602141	A	20000623
			US 2000636803	A	20000810
			US 2001814460	A	20010321
			US 2001992277	A	20011114
WO 200341612	A2	20030522	WO 2002US36492	A	20021113 200344

Priority Applications (No Type Date): US 2001992277 A 20011114; US 99398991 A 19990917; US 99434653 A 19991105; US 2000513039 A 20000225; US 2000513432 A 20000225; US 2000602141 A 20000623; US 2000636803 A 20000810 ; US 2001814460 A 20010321

## Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
US 20020035994	A1	15	A61F-005/56	CIP of application US 99398991
				CIP of application US 99434653
				CIP of application US 2000513039
				CIP of application US 2000513432
				CIP of application US 2000602141
				CIP of application US 2000636803
				CIP of application US 2001814460
				CIP of patent US 6250307
US 6502574	B2		A61F-005/56	CIP of application US 99398991
				CIP of application US 99434653
				CIP of application US 2000513039
				CIP of application US 2000513432
				CIP of application US 2000602141
				CIP of application US 2000636803
				CIP of application US 2001814460
				CIP of patent US 6250307

WO 200341612 A2 E A61F-000/00

Designated States (National): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

Designated States (Regional): AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW

Abstract (Basic): US 20020035994 A1

NOVELTY - The locations on the right and left sides of a soft **palate** (SP), separated by an anterior-posterior midline, are linked by a **submucosal** linkage of stiffness greater than the stiffness of untreated tissue between the locations.

USE - For treating snoring by lateral stiffening of soft **palate** using **implants** such as modular **implant**, elongated **implant**, braided **implant**, expandable **implant**, sheet **implant**, particulate **implant**, radio frequency ablation, sclerosing agent.

ADVANTAGE - The right and left sides of the patient's **palate** are linked by a simple technique.

DESCRIPTION OF DRAWING(S) - The figure shows a side sectional view of human head showing soft **palate** and adjacent anatomical features.

pp; 15 DwgNo 1/20

Derwent Class: A96; D22; P32

International Patent Class (Main): A61F-000/00; A61F-005/56

17/34/3 (Item 3 from file: 350)

DIALOG(R)File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

011822301

WPI Acc No: 1998-239211/199821

Cell-scaffold composition, for growing cartilage in vivo - comprises a three-dimensional scaffold of biodegradable, synthetic polymer fibres and cartilage-producing cells attached to fibre surface

Patent Assignee: CHILDRENS MEDICAL CENT (CHIL-N); MASSACHUSETTS INST TECHNOLOGY (MASI )

Inventor: LANGER R S; VACANTI C A; VACANTI J P

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
US 5736372	A	19980407	US 86933018	A	19861120	199821 B
			US 87123579	A	19871120	
			US 89339155	A	19890417	
			US 90509952	A	19900416	

Priority Applications (No Type Date): US 90509952 A 19900416; US 86933018 A 19861120; US 87123579 A 19871120; US 89339155 A 19890417

Patent Details:

Patent No	Kind	Lan Pg	Main IPC	Filing Notes
US 5736372	A	17	C12N-011/08	CIP of application US 86933018
				CIP of application US 87123579
				CIP of application US 89339155
				CIP of patent US 5041138

Abstract (Basic): US 5736372 A

The following are claimed: (A) a cell-scaffold composition for growing cells to produce a functional cartilaginous structure in vivo, comprising: (a) a fibrous three-dimensional scaffold, which is composed of fibres of a biodegradable, synthetic polymer, and (b) cartilage-producing cells, which are attached to the surface of the fibres of the scaffold, and which are attached uniformly throughout the scaffold. The fibres are spaced apart, so that the average interfibre distance is 100-300  $\mu$ m. The fibres provide sufficient surface area to allow attachment of a density of cells which is sufficient to produce the functional cartilaginous structure in vivo. Diffusion in the scaffold provides free exchange of nutrients, gases and waste to and from the cells, so that cell viability can be maintained throughout the scaffold prior to formation of the functional cartilage in vivo; (B) a cell-scaffold composition comprising: (a) a fibrous three-dimensional scaffold, which is composed of fibres of a synthetic polymer, and (b) cartilage-producing cells, which are attached to the surface of the fibres of the scaffold, and which are attached uniformly throughout the scaffold. The fibres are separated by a distance sufficient to allow (i) multiple layers of cells to adhere to the surface of the fibres and (ii) to provide free exchange (by diffusion) of nutrients and waste to the attached cells, when the cells on the scaffold are cultured in a nutrient medium. The scaffold is in the form of an **ear**, a **nose**, or a component of an **ear** or a **nose**.

The polymer is a polyanhydride, polyorthoester, polyglycolic acid, polylactic acid and/or their copolymer. The scaffold is formed from a combination of biodegradable and non-biodegradable materials. The non-biodegradable material is polytetrafluoroethylene, nylon, ethylene

Serial 09/857307

August 13, 2003

vinyl acetate and/or a polyester. The composition also comprises a coating on the fibres. The coating is a **basement membrane** component, agar, agarose, gelatin, a glycosaminoglycan a collagen, gum arabic, fibronectin, laminin, hyaluronic acid and/or an attachment peptide. The cells are chondrocyte cells, fibroblast cells capable of differentiation into chondrocytes, or bone precursor cells capable of differentiation into chondrocytes.

USE - The cell scaffold compositions may be used for production of joint relinings, growth of elastic cartilage for plastic or reconstructive replacement of cartilage structures (e.g. the **ear** or the **nose** ), or for repair of large bone defects.

ADVANTAGE - The compositions can be cast or molded into desired shapes, or can be manipulated at the time of **implantation** . The cells can retain their normal morphology and cell function.

Dwg.0/10

Derwent Class: A96; B04; D16; D22; P32

International Patent Class (Main): C12N-011/08

International Patent Class (Additional): A61F-002/18; A61F-002/28; C12N-005/00

17/34/4 (Item 4 from file: 350)

DIALOG(R) File 350:Derwent WPIX

(c) 2003 Thomson Derwent. All rts. reserv.

008461275

WPI Acc No: 1990-348275/199046

Formation of cartilage structures - by attaching chondrocyte cells to biocompatible matrix in nutrient environment

Patent Assignee: LANGER R S (LANG-I); VACANTI C A (VACA-I); VACANTI J P (VACA-I); CHILDRENS MEDICAL CENT (CHIL-N); MASSACHUSETTS INST TECHNOLOGY (MASI ); CHILDRENS HOSP BOSTON (CHIL-N); CHILDRENS MEDICAL CENTER CORP (CHIL-N); CHILDRENS HOSP ROSTON (CHIL-N)

Inventor: LANGER R S; VACANTI C A; VACANTI J P

Number of Countries: 020 Number of Patents: 011

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
WO 9012603	A	19901101			199046	B
AU 9055568	A	19901116			199107	
US 5041138	A	19910820	US 89339155	A	19890417	199136
EP 469070	A	19920205	EP 90907835	A	19900416	199206
JP 4505717	W	19921008	JP 90507077	A	19900416	199247
			WO 90US2091	A	19900416	
AU 635025	B	19930311	AU 9055568	A	19900416	199317
JP 94006155	B2	19940126	JP 90507077	A	19900416	199407
			WO 90US2091	A	19900416	
EP 469070	B1	19960911	EP 90907835	A	19900416	199641
			WO 90US2091	A	19900416	
CA 2051663	C	19960806	CA 2051663	A	19900416	199642
DE 69028524	E	19961017	DE 628524	A	19900416	199647
			EP 90907835	A	19900416	
			WO 90US2091	A	19900416	
ES 2095252	T3	19970216	EP 90907835	A	19900416	199714

Priority Applications (No Type Date): US 89339155 A 19890417; US 86933018 A 19861120; US 87123579 A 19871120

Cited Patents: EP 282746; EP 339607; US 4553272; US 4846835; WO 8803785; WO 8900413; 3.Jnl.Ref

Patent Details:

Patent No	Kind	Lan	Pg	Main IPC	Filing Notes
WO 9012603	A		45		
Designated States (National): AU CA FI JP KR NO					
Designated States (Regional): AT BE CH DE DK ES FR GB IT LU NL SE					
EP 469070	A				
Designated States (Regional): AT BE CH DE ES FR GB IT LI LU NL SE					
JP 4505717	W	45	A61L-027/00	Based on patent WO 9012603	
AU 635025	B		A61L-027/00	Previous Publ. patent AU 9055568	
				Based on patent WO 9012603	
JP 94006155	B2		A61L-027/00	Based on patent JP 4505717	
				Based on patent WO 9012603	
EP 469070	B1	E	22	A61L-027/00	Based on patent WO 9012603
Designated States (Regional): AT BE CH DE DK ES FR GB IT LI LU NL SE					
CA 2051663	C			C12N-011/00	
DE 69028524	E			A61L-027/00	Based on patent EP 469070
					Based on patent WO 9012603
ES 2095252	T3			A61L-027/00	Based on patent EP 469070

Abstract (Basic): WO 9012603 A

A system for growing a cartilaginous structure is claimed comprising a biocompatible matrix in a nutrient environment and chondrocyte cells attached to the matrix, where the matrix is structured to provide free exchange of nutrients and waste to the attached cells in the absence of vascularisation. The matrix may be formed from eg. polyanhydrides, polyorthoesters, polyglycolic acids, polylactic acids, collagen, teflon, nylon, ethylene vinyl acetate or polyesters. The matrix may be coated with eg. **basement membrane** components, agar, agarose, gelatin, gum arabic, collagens, fibronectin, laminin, hyaluronic acid, glycosaminoglycans or attachment peptides.

Also claimed is a method for making a cartilaginous structure by providing a biocompatible matrix in a nutrient environment and attaching cartilage cells to the matrix.

USE/ADVANTAGE - The matrices can be formed of the required shape and flexibility for reconstructive and plastic surgery and are able to produce high cell densities. They can be used *in vivo* for eg. the growth of hyaline cartilage for joint relinings, the growth of elastic cartilage for plastics or reconstructive replacement of cartilage structures or repair of large bone defects. They can also be used for the prodn. of bioactive molecules *in vitro*, eg. proteinase inhibitors and collagenase inhibitors.

(Dwg. 0/10

Abstract (Equivalent): EP 469070 B

Use of a biocompatible synthetic polymeric matrix, the matrix being formed of fibres or a fibrous mesh and made from either a non-degradable material or a biodegradable material which degrades by hydrolysis or a combination thereof and chondrocytes, fibroblasts or bone-precursor cells attached to the matrix, wherein the matrix is structured to provide free exchange of nutrients and waste to the attached said cells in the absence of vascularisation in the manufacture of a cartilaginous structure or surface, or a bone structure, for **implantation** in, or addition to, a patient, wherein the said matrix is formed into a desired shape of a cartilaginous structure or surface or for repair of a bone defect in the said patient.

(Dwg. 0/10

Abstract (Equivalent): US 5041138 A

Process for replacing or repairing cartilage structures comprises immobilising living cells on a rigid or flexible biocompatible, biodegradable synthetic polymer matrix, pref. coated with membrane components; proliferation of the cells *in vitro*; and **implantation**. Cells which propagate under these

Serial 09/857307

August 13, 2003

conditions are cartilage, bone, skin and nerve cells. USE - The process is applicable to the repair or replacement of cartilage damaged by inflammation, trauma, ageing or congenital defect, or replacement of bone, **nose** and **ear** tissues, etc. (8pp

Derwent Class: B04; D16; D22; P32; P34

International Patent Class (Main): A61L-027/00; C12N-011/00

International Patent Class (Additional): A61F-002/30; A61K-037/00; C07C-245/00; C12N-005/00

Serial 09/857307

August 13, 2003

File 348:EUROPEAN PATENTS 1978-2003/Jul W03

File 349:PCT FULLTEXT 1979-2002/UB=20030807,UT=20030731

Set	Items	Description
S1	5268	SUBMUCOSA? ? OR (BASEMENT OR HYALINE) () MEMBRANE? ? OR (BAS- AL OR BASEMENT) () LAMINA? ?
S2	4960	VOCAL() (CORD? ? OR FOLD? ?) OR LARYNX OR LARYNGE? OR PALAT- E? ? OR PALATAL
S3	66820	NASAL OR NOSE OR AURICULA? ? OR EAR OR EARS
S4	674	(HEAD OR NECK) (2N) TISSUE
S5	48963	GRAFT? OR HOMOGRAFT? OR HETEROGRAFT? OR ALLOGRAFT? OR AUTO- GRAFT?
S6	98506	IMPLANT? OR TRANSPLANT?
S7	3878	IC=A61L-027
S8	13728	IC=A61F-002
S9	151	S1(5N)S5:S6
<b>S10</b>	<b>5</b>	<b>S9(S)S2:S4</b>
S11	160	S1(S)S2:S4
S12	830	S7 AND S8
<b>S13</b>	<b>1</b>	<b>S11 AND S12</b>
S14	158	S1(S)S2:S3
S15	25	S5:S6(S)S14
<b>S16</b>	<b>20</b>	<b>S15 NOT (S10 OR S13)</b>
S17	0	S7:S8 AND S16

10/6/2 (Item 1 from file: 349)

00955524

MEDICAL DEVICE

10/6/3 (Item 2 from file: 349)

00809860

MEDICAL DEVICE

10/6/4 (Item 3 from file: 349)

00568881

METHOD FOR VOCAL CORD RECONSTRUCTION

13/3,AB,K/1 (Item 1 from file: 349)

DIALOG(R)File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00817537

**METHODS AND COMPOSITIONS FOR RECONSTRUCTION OF MULTILAYERED TISSUE STRUCTURES  
PROCEDES ET COMPOSITIONS POUR RECONSTRUIRE DES STRUCTURES TISSULAIRES  
MULTICOUCHES**

Patent Applicant/Assignee:

CHILDREN'S MEDICAL CENTER CORPORATION, 300 Longwood Avenue, Boston, MA  
02115, US, US (Residence), US (Nationality)

Inventor(s):

ATALA Anthony, 74 Westerly Road, Weston, MA 02193, US,

Legal Representative:

ENGELLENNER Thomas J (et al) (agent), Nutter, McClellan & Fish, LLP, One  
International Place, Boston, MA 02110-2699, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200149827 A1 20010712 (WO 0149827)

Application: WO 2000US33811 20001214 (PCT/WO US0033811)

Priority Application: US 99474524 19991229

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ

Serial 09/857307

August 13, 2003

DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ  
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG  
SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW  
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR  
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG  
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW  
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 11226

English Abstract

The invention is directed to compositions and methods of producing multilayered artificial organs comprising heterogenous polylayers. Polylayers comprising homogenous cell populations are created on one side of a biocompatible substrate such that a chimeric interface is produced between the heterogenous polylayers. Cellular interaction at the chimeric interface produce an interstitial biomaterial with morphological and functional characteristics that resemble the natural *in vivo* organ.

International Patent Class: **A61F-002/04 ...****... A61L-027/38**

Fulltext Availability:

Detailed Description

Detailed Description

... interactions which result in the formation of biological material, such as epithelial cells, like, bladder **submucosa**, oral mucosa and **nasal** epithelium. The presence of the **submucosa** provides growth factors and other proteins which promote normal division and differentiation...

16/6/1 (Item 1 from file: 348)

00774005

**KERATINOCYTE GROWTH FACTOR ANALOGS**

16/6/2 (Item 2 from file: 348)

00773565

**ANALOGS OF KERATINOCYTE GROWTH FACTOR**

16/6/3 (Item 1 from file: 349)

00944588

**KERATINOCYTE GROWTH FACTOR-2**

16/6/13 (Item 11 from file: 349)

00434349

**KERATINOCYTE GROWTH FACTORS AND THEIR USE IN COMBINATION WITH GLUCAGON-LIKE PEPTIDE DERIVATIVES**

16/6/14 (Item 12 from file: 349)

00426179

**KERATINOCYTE GROWTH FACTOR-2 PRODUCTS**

16/6/15 (Item 13 from file: 349)

00399410

**AL-2 NEUROTROPHIC FACTOR**

16/6/17 (Item 15 from file: 349)

00357661

**STROMAL CELL-BASED THREE-DIMENSIONAL CULTURE SYSTEM FOR FORMING TUBES,  
TENDONS, LIGAMENTS AND CORRECTIVE STRUCTURES**

16/6/18 (Item 16 from file: 349)

00329440

**KERATINOCYTE GROWTH FACTOR ANALOGS**

16/6/19 (Item 17 from file: 349)

00329438

**ANALOGS OF KERATINOCYTE GROWTH FACTOR**

16/3,AB,K/8 (Item 6 from file: 349)

DIALOG(R) File 349:PCT FULLTEXT

(c) 2003 WIPO/Univentio. All rts. reserv.

00800361

**AUGMENTATION AND REPAIR OF AGE-RELATED SOFT TISSUE DEFECTS**

**AUGMENTATION ET REPARATION DES IMPERFECTIONS DES TISSUS MOUS LIES A L'AGE**

Patent Applicant/Assignee:

GERIGENE MEDICAL CORPORATION, 535 Science Drive, Madison, WI 53711, US, US (Residence), US (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

KLEINSEK Don A, W5036N County Highway A, Elkhart Lake, WI 53020, US, US (Residence), US (Nationality), (Designated only for: US)

SOTO Adriana, W5036N County Highway A, Elkhart Lake, WI 53703, US, US (Residence), CO (Nationality), (Designated only for: US)

Legal Representative:

SCANLON William J (agent), The Scanlon Law Office, 616 South Ingersoll Street, Suite 1, Madison, WI 53703-3810, US,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200132129 A2-A3 20010510 (WO 0132129)

Application: WO 2000US30623 20001106 (PCT/WO US0030623)

Priority Application: US 99163734 19991105

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR  
(OA) BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG  
(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZW  
(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 25243

English Abstract

The present invention discloses methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or direct surgical placement/implantation of autologous cultured cells and/or cultured cell-produced extracellular matrix that is derived from connective tissue, dermis, fascia, lamina propria, stroma, adipose tissue, muscle, tendon, ligament or the hair follicle. The corrective application is done on tissue proximal or within the area of the defect. The method involves retrieving viable cells from the subject, a neonate or human fetus. Alternatively, the corrective

application involves the cells placed in a matrix, preferably comprised of autologous extracellular matrix constituents as a three-dimensional structure or as a suspension, prior to placement into a position with respect to the subject's defect. In a further embodiment, the preferable autologous extracellular matrix constituents are collected from culture and placed in a position with respect to the subject's defect.

Fulltext Availability: Claims

Claim

... The extraction site can be any cartilage bearing area of the body such as the **ears** or joints. Cartilage isolated from a small 3x6mm **ear** punch biopsy or through arthroscopic surgery of a knee is chilled in sterile saline solution...point) from the initial entry point of the passer needle. The dermal or fascial fibroblast **graft** is then pulled into the passer needle and its position may be adjusted by pulling...

...passer needle is pulled backward and removed, thus resulting in the final placement of the **graft** following the final cutting of the remaining suture. Fascial or dermal **grafts** can be placed in either the subcutaneous., dermal or fascial layers for many of the skin defects to be augmented or repaired. Similar **grafts** can be placed in the dermal and subcutaneous layers for treating cellulite. Fascial and dermal **grafts** can be placed in the dermal, subcutaneous, fascial and subjacent areas of the wound area... Fascial flaps made of the autologous fascial cells and/or extracellular matrix can replace mesh **implants**, be used for layer closure techniques or be sutured into the fascial layers of the...